| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122°F (50°C) |
| Altitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical input power | 3 phase from 0 to V supply |
\n\n## AQUAVAR® IPC VARIABLE SPEED CONTROLLER \n\n## FEATURES \n\n- EASIER start-up and programming with Start-Up Genie- Wide range of standard and permanent magnet motors with power up to 600 hp- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)- Remote commissioning and monitoring with USB connectivity and software- Two wire multi-pump connection for faster installation- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation- System redundancy with multi-master control in case of drive failure- BACnet and Modbus as a standard for seamless BMS integration- Submersible and above ground applications- Wide range of voltage and enclosure options- True 208 V coverage- Dedicated single phase input- Remote commissioning and monitoring with USB connectivity and software- In-panel or handheld keypad with backlit display- Alarm Log for last 5 alarms and maintenance events- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference- I/O expansion cards, factory installed or field configured", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00003/document_with_boxes.png", "raw_response_path": "sample_00003/raw_response.md", "source_image_path": "sample_00003/source.png", "figures": [{"figure_id": "sample_00003_fig01", "image_path": "sample_00003/figures/sample_00003_fig01.png", "description": "", "image": "sample_00003/figures/sample_00003_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00003_fig01\", \"image_path\": \"sample_00003/figures/sample_00003_fig01.png\", \"description\": \"\"}"]}
-{"sample_id": "sample_00004", "dataset_index": 4, "document_markdown_path": "sample_00004/document.md", "document_markdown_text": "2645-9248 Journal homepage: www.jidhealth.com Open A ccess \n\n# A case report on generalized pemphigus vulgaris treated with rituximaba \n\nJ agdish J adavbhai Sakhiya \\(^{1\\ast}\\) , Dhruv J agdish Sakhiya \\(^{1}\\) , J ashmine Mukeshbhai Gandhi \\(^{1}\\) , F eral Ravi Daruwala \\(^{2}\\) \n\n## Abstract \n\nBackground: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris. \n\nCase presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed. \n\nConclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails. \n\nKeywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India \n\n## Background \n\nThe term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus folicaceus (PF). PV is the most common subtype and represents well over \\(80\\%\\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of \n\nimmune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00004/document_with_boxes.png", "raw_response_path": "sample_00004/raw_response.md", "source_image_path": "sample_00004/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00005", "dataset_index": 5, "document_markdown_path": "sample_00005/document.md", "document_markdown_text": "1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine. \n\nInformation Pertinent to Performance of the Procedure \n\n- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).- Patient's ability to lie still for 20-40 min for PET to \\(\\sim 1\\) h for SPECT. \n\n## Precautions and Conscious Sedation \n\n- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients. \n\n## Radiopharmaceutical \n\n## Radiopharmaceutical \n\n- [18F]Fluoro-2-deoxyglucose (FDG). \n- 3-[123I]Iodo-α-methyl-L-tyrosine (IMT). \n- [Methyl-11C]-L-methionine (MET). \n- \\(O-(2-[18F]\\mathrm{Fluoroethyl}) - \\mathrm{L}\\) -tyrosine (FET). \n\n## Recommended Dosage \n\nThe dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode. \n\n- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants. \n- IMT: 100-400 MBq (typically 185 MBq). \n- MET: 200-250 MBq. \n- FET: 200-250 MBq. \n\nThe administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group. \n\n## Radiation Dosimetry (Table 2.1) \n\n## Radiation Dosimetry of Brain Transmission Scans \n\nBased on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \\(\\sim 20 \\mu \\mathrm{Sv}\\) for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00005/document_with_boxes.png", "raw_response_path": "sample_00005/raw_response.md", "source_image_path": "sample_00005/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00006", "dataset_index": 6, "document_markdown_path": "sample_00006/document.md", "document_markdown_text": "1? (X) 1? (X) 1? (X) 1? (X) 1? (X) 1? (X) \n\nEntry for the Engineers Ireland Biomedical Research Medal? (X) \n\nPost- Doctoral Researcher/Senior Researcher/PI \n\n## LOAD INDUCED CHANGES IN COLLAGEN FIBRE ARCHITECTURE IN ARTERIES CHARACTERISED BY SMALL ANGLE LIGHT SCATTERING \n\nGaul, R.1,2, Lally, C.1,2 1Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, Ireland. 2School of Engineering, Trinity College Dublin, Dublin, Ireland. email: rgau@tcd.ie \n\n## INTRODUCTION \n\nThe structural strength of arteries is governed by reinforcing collagen fibres present in the vessel wall. Although healthy vessels are capable of fibre remodelling, unhealthy fibre remodelling patterns may be associated with disease [1]. A greater understanding of the remodelling of these fibres may provide greater insight into arteries at risk of disease and how arterial repair may be induced. \n\nSmall angle light scattering (SALS) is a technique which has previously been used to determine the structure of thin, highly organised tissue structures, such as bovine pericardium and porcine aortic valve tissue [2]. \n\nThe aim of the present study is to design and develop a fully automated SALS system capable of determining the changes in arterial fibre architecture in response to strain. \n\n## MATERIALS AND METHODS \n\nAn in- house SALS system has been developed making use of an unpolarised 5mW HeNe laser \\((\\lambda = 632.8 \\text{nm})\\) and two focusing lenses in order to pass light through a tissue sample held in an automated sample positioner. The sample positioner incorporates two stepper motors controlled by LabVIEW to allow movement of the sample in the x and y plane with a resolution of \\(5 \\mu \\text{m}\\) . The sample is interrogated sequentially in \\(250 \\times 250 \\mu \\text{m}\\) regions. The resulting scattered light pattern is recorded by a CMOS camera and analysed through a custom Matlab code to determine predominant collagen fibre directions. \n\nTo validate the system, testing was conducted on test plates with known printed configurations. Once validated, SALS testing was carried out on flat porcine carotid artery wall sections fixed at different stretch ratios. Carotid artery samples were fixed and processed using a standard histological tissue sectioning protocol. Validation of the results was achieved through histological staining of the sections. \n\n## RESULTS \n\nFigure 1a displays the collagen fibre directions in an unstretched carotid artery section, as predicted by SALS, overlaid on picrosirius red stained histological images. Figure 1b shows the reorganisation of the constituent collagen fibres under circumferential stretch \\((\\lambda = 1.25)\\) . \n\nCollagen fibre patterns in the artery were also obtained through the thickness of the artery wall using SALS, for both strained and unstrained configurations. \n\n\n\n| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50°C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
\n\n## FEATURES \n\n- Easier start-up and programming with Start-Up Genie\n- Wide range of standard and permanent magnet motors with power up to 600 hp\n- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)\n- Remote commissioning and monitoring with USB connectivity and software\n- Two wire multi-pump connection for faster installation\n- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation\n- System redundancy with multi-master control in case of drive failure\n- BACnet and Modbus as a standard for seamless BMS integration\n- Submersible and above ground applications\n- Wide range of voltage and enclosure options\n- True 208 V coverage\n- Dedicated single phase input\n- Remote commissioning and monitoring with USB connectivity and software\n- In-panel or handheld keypad with backlit display\n- Alarm Log for last 5 alarms and maintenance events\n- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference\n- I/O expansion cards, factory installed or field configured", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00003/document_with_boxes.png", "raw_response_path": "sample_00003/raw_response.md", "source_image_path": "sample_00003/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00004", "dataset_index": 4, "document_markdown_path": "sample_00004/document.md", "document_markdown_text": "2645-9248 Journal homepage: www.jidhealth.com Open Acess Original Article \n\n# A case report on generalized pemphigus vulgaris treated with rituximaba \n\nJ agdish J adavbhai Sakhiya \\(^{1\\ast}\\) , Dhruv J agdish Sakhiya \\(^{1}\\) , J ashmine Mukeshbhai Gandhi \\(^{1}\\) , Feral Ravi Daruwala \\(^{2}\\) \n\n## Abstract \n\nBackground: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris. \n\nCase presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed. \n\nConclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails. \n\nKeywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India \n\n## Background \n\nThe term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \\(80\\%\\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00004/document_with_boxes.png", "raw_response_path": "sample_00004/raw_response.md", "source_image_path": "sample_00004/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00005", "dataset_index": 5, "document_markdown_path": "sample_00005/document.md", "document_markdown_text": "1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine. \n\nInformation Pertinent to Performance of the Procedure \n\n- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI). \n\nPrecautions and Conscious Sedation \n\n- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients. \n\nRadiopharmaceutical \n\nRadiopharmaceutical \n\n- [18F]Fluoro-2-deoxyglucose (FDG). \n- 3-\\[^{123}\\mathrm{I}\\]Iodo-α-methyl-L-tyrosine (IMT). \n- \\[ \\mathrm{Methyl-}^{11}\\mathrm{C} \\]-L-methionine (MET). \n- \\(O-(2-[^{18}\\mathrm{F}]\\mathrm{Fluoroethyl})-L\\)-tyrosine (FET). \n\n## Recommended Dosage \n\nThe dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET-cameras with BGO- crystals in 3D- mode. \n\n- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants. \n- IMT: 100-400 MBq (typically 185 MBq). \n- MET: 200-250 MBq. \n- FET: 200-250 MBq. \n\nThe administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group. \n\n## Radiation Dosimetry (Table 2.1) \n\nRadiation Dosimetry of Brain Transmission Scans \n\nBased on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \\(\\sim 20\\) μSv for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00005/document_with_boxes.png", "raw_response_path": "sample_00005/raw_response.md", "source_image_path": "sample_00005/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00006", "dataset_index": 6, "document_markdown_path": "sample_00006/document.md", "document_markdown_text": "1) (X) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 2) 1) 1) 1) 1) 1) 1) 1) 1) 1) 3) 1) 1) 1) 1) 1) 1) 1) 1) 1) 4) 1) 1) 1) 1) 1) 1) 1) 1) 1) 5) 1) 1) 1) 1) 1) 1) 1) 1) 6) 1) 1) 1) 1) 1) 1) 1) 1) 1) 7) 1) 1) 1) 1) 1) 1) 1) 1) 1) 8) 1) 1) 1) 1) 1) 1) 1) 1) 1) 9) 1) 1) 1) 1) 1) 1) 1) 1) 1) 10) 1) 1) 1) 1) 1) 1) 1) 1) 1) 11) 1) 1) 1) 1) 1) 1) 1) 1) 1) 12) 1) 1) 1) 1) 1) 1) 1) 1) 1) 13) 1) 1) 1) 1) 1) 1) 1) 1) 1) 14) 1) 1) 1) 1) 1) 1) 1) 1) 1) 15) 1) 1) 1) 1) 1) 1) 1) 1) 1) 16) 1) 1) 1) 1) 1) 1) 1) 1) 1) 17) 1) 1) 1) 1) 1) 1) 1) 1) 1) 18) 1) 1) 1) 1) 1) 1) 1) 1) 1) 19) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 20) 1) 1) 1) 1) 1) 1) 1) 1) 1) 21) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 22) 1) 1) 1) 1) 1) 1) 1) 1) 1) 23) 1) 1) 1) 1) 1) 1) 1) 1) 1) 24) 1) 1) 1) 1) 1) 1) 1) 1) 1) 25) 1) 1) 1) 1) 1) 1) 1) 1) 1) 26) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 27) 1) 1) 1) 1) 1) 1) 1) 1) 1) 28) 1) 1) 1) 1) 1) 1) 1) 1) 1) 29) 1) 1) 1) 1) 1) 1) 1) 1) 30) 1) 1) 1) 1) 1) 1) 1) 1) 1) 31) 1) 1) 1) 1) 1) 1) 1) 1) 1) 32) 1) 1) 1) 1) 1) 1) 1) 1) 1) 33) 1) 1) 1) 1) 1) 1) 1) 1) 1) 34) 1) 1) 1) 1) 1) 1) 1) 1) 1) 35) 1) 1) 1) 1) 1) 1) 1) 1) 1) 36) 1) 1) 1) 1) 1) 1) 1) 1) 1) 37) 1) 1) 1) 1) 1) 1) 1) 1) 1) 38) 1) 1) 1) 1) 1) 1) 1) 1) 1) 39) 1) 1) 1) 1) 1) 1) 1) 1) 1) 40) 1) 1) 1) 1) 1) 1) 1) 1) 1) 41) 1) 1) 1) 1) 1) 1) 1) 1) 1) 42) 1) 1) 1) 1) 1) 1) 1) 1) 1) 43) 1) 1) 1) 1) 1) 1) 1) 1) 1) 44) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 45) 1) 1) 1) 1) 1) 1) 1) 1) 1) 46) 1) 1) 1) 1) 1) 1) 1) 1) 1) 47) 1) 1) 1) 1) 1) 1) 1) 1) 1) 48) 1) 1) 1) 1) 1) 1) 1) 1) 1) 49) 1) 1) 1) 1) 1) 1) 1) 1) 1) 50) 1) 1) 1) 1) 1) 1) 1) 1) 1) 51) 1) 1) 1) 1) 1) 1) 1) 1) 1) 52) 1) 1) 1) 1) 1) 1) 1) 1) 1) 53) 1) 1) 1) 1) 1) 1) 1) 1) 1) 54) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 55) 1) 1) 1) 1) 1) 1) 1) 1) 1) 56) 1) 1) 1) 1) 1) 1) 1) 1) 1) 57) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 58) 1) 1) 1) 1) 1) 1) 1) 1) 1) 59) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 60) 1) 1) 1) 1) 1) 1) 1) 1) 1) 61) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 62) 1) 1) 1) 1) 1) 1) 1) 1) 1) 63) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 64) 1) 1) 1) 1) 1) 1) 1) 1) 1) 65) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 66) 1) 1) 1) 1) 1) 1) 1) 1) 1) 67) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 68) 1) 1) 1) 1) 1) 1) 1) 1) 1) 69) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 70) 1) 1) 1) 1) 1) 1) 1) 1) 1) 71) 1) 1) 1) 1) 1) 1) 1) 1) 1) 72) 1) 1) 1) 1) 1) 1) 1) 1) 1) 73) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 74) 1) 1) 1) 1) 1) 1) 1) 1) 1) 75) 1) 1) 1) 1) 1) 1) 1) 1) 1) 76) 1) 1) 1) 1) 1) 1) 1) 1) 1) 77) 1) 1) 1) 1) 1) 1) 1) 1) 1) 78) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 79) 1) 1) 1) 1) 1) 1) 1) 1) 1) 80) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 81) 1) 1) 1) 1) 1) 1) 1) 1) 1) 82) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 83) 1) 1) 1) 1) 1) 1) 1) 1) 1) 84) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 85) 1) 1) 1) 1) 1) 1) 1) 1) 1) 86) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 87) 1) 1) 1) 1) 1) 1) 1) 1) 1) 88) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 89) 1) 1) 1) 1) 1) 1) 1) 1) 1) 90) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 91) 1) 1) 1) 1) 1) 1) 1) 1) 92) 1) 1) 1) 1) 1) 1) 1) 1) 1) 93) 1) 1) 1) 1) 1) 1) 1) 1) 1) 94) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 95) 1) 1) 1) 1) 1) 1) 1) 1) 1) 96) 1) 1) 1) 1) 1) 1) 1) 1) 1) 97) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 98) 1) 1) 1) 1) 1) 1) 1) 1) 1) 99) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 100) 1) 1) 1) 1) 1) 1) 1) 1) 1) 101) 1) 1) 1) 1) 1) 1) 1) 1) 1) 102) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 103) 1) 1) 1) 1) 1) 1) 1) 1) 1) 104) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 105) 1) 1) 1) 1) 1) 1) 1) 1) 1) 106) 1) 1) 1) 1) 1) 1) 1) 1) 1) 107) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 108) 1) 1) 1) 1) 1) 1) 1) 1) 1) 109) 1) 1) 1) 1) 1) 1) 1) 1) 1) 110) 1) 1) 1) 1) 1) 1) 1) 1) 1) 111) 1) 1) 1) 1) 1) 1) 1) 1) 1) 112) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 113) 1) 1) 1) 1) 1) 1) 1) 1) 1) 114) 1) 1) 1) 1) 1) 1) 1) 1) 115) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 116) 1) 1) 1) 1) 1) 1) 1) 1) 1) 117) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 118) 1) 1) 1) 1) 1) 1) 1) 1) 1) 119) 1) 1) 1) 1) 1) 1) 1) 1) 120) 1) 1) 1) 1) 1) 1) 1) 1) 1) 121) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 122) 1) 1) 1) 1) 1) 1) 1) 1) 1) 123) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 124) 1) 1) 1) 1) 1) 1) 1) 1) 1) 125) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 126) 1) 1) 1) 1) 1) 1) 1) 1) 1) 127) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 128) 1) 1) 1) 1) 1) 1) 1) 1) 1) 129) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 130) 1) 1) 1) 1) 1) 1) 1) 1) 1) 131) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 132) 1) 1) 1) 1) 1) 1) 1) 1) 1) 133) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) 134) 1) 1", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00006/document_with_boxes.png", "raw_response_path": "sample_00006/raw_response.md", "source_image_path": "sample_00006/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00007", "dataset_index": 7, "document_markdown_path": "sample_00007/document.md", "document_markdown_text": "2011, XLVI, 394 p., HardcoverISBN: 978-90-481-8664-8", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00007/document_with_boxes.png", "raw_response_path": "sample_00007/raw_response.md", "source_image_path": "sample_00007/source.png", "figures": [], "figures_metadata": []}
{"sample_id": "sample_00008", "dataset_index": 8, "document_markdown_path": "sample_00008/document.md", "document_markdown_text": "The parametric equations for a projectile with constant gravity g: \n\n\\[x = v_0 t \\cos \\theta + x_0\\]\n\n\\[y = -\\frac{1}{2} gt^2 + v_0 t \\sin \\theta + y_0\\]\n\nex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find: \n\n1. \\(\\vec{r}(t)\\) \n\n2. the maximum altitude attained \n\n3. the range of the shell \n\n4. the speed on impact \n\n5. the horizontal distance when \\(y = 2240\\) ft.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00008/document_with_boxes.png", "raw_response_path": "sample_00008/raw_response.md", "source_image_path": "sample_00008/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00009", "dataset_index": 9, "document_markdown_path": "sample_00009/document.md", "document_markdown_text": "4) purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at 140 kV, which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \\(< 10\\) s). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction.\n\n- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over 15–30 min aiming to collect 50–200 million counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. \n\n## IMT Single Photon Emission Tomography \n\n- Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images. \n\n- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \\(^{123}\\)I may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. \n\n## TABLE 2.2. Acquisition parameters for IMT-SPECT \n\n- Rotational radius: smallest possible with appropriate patient safeguard\n- Matrix: \\(128 \\times 128\\)\n- Angular sampling: \\(\\leq 3^{\\circ}\\) (360° rotation)\n- Zoom: acquisition pixel size should be 1/3–1/2 of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size\n- Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort\n- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30–50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00009/document_with_boxes.png", "raw_response_path": "sample_00009/raw_response.md", "source_image_path": "sample_00009/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00010", "dataset_index": 10, "document_markdown_path": "sample_00010/document.md", "document_markdown_text": "Do: An electron in a TV tube is beamed horizontally at a speed of 5 x \\(10^{6}\\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used? \n\na. \\(y = -4.9t^{2}\\) \n\nb. \\(y = -4.9t^{2} - 5x10^{6}t\\) \n\nc. \\(5x10^{6}t = 4\\) \n\nd. \\(5x10^{6}t = 40\\)", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00010/document_with_boxes.png", "raw_response_path": "sample_00010/raw_response.md", "source_image_path": "sample_00010/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00011", "dataset_index": 11, "document_markdown_path": "sample_00011/document.md", "document_markdown_text": "0.5cm 0.5cm 0.5cm 0.5cm 0.5cm 0.5cm 0.5cm\n\n\n\n# Brett Babin\n\nPostdoctoral Research Fellow, Pathology\n\n☉ Curriculum Vitae available Online\n\n# Bio\n\n# BIO\n\nBrett received his B.S. in Chemical Engineering from the University of Massachusetts Amherst in 2009. There he worked in the lab of Dr. Neil Forbes developing microfluidic devices to study the interactions between bacteria and in vitro tumor models. He earned his Ph.D. in Chemical Engineering from the California Institute of Technology in 2016 where he worked with Dr. Dave Tirrell and Dr. Dianne Newman. His thesis focused on the development and application of a method for time- and cell-selective proteomic analysis in bacteria. He used this approach to study protein synthesis by the opportunistic pathogen Pseudomonas aeruginosa under dormancy and biofilm growth conditions. Brett joined the Bogyo lab at Stanford in the fall of 2016. His current focus is on the roles of serine hydrolases in the physiology of pathogenic bacteria.\n\n# HONORS AND AWARDS\n\n·A.P. Giannini Postdoctoral Fellowship, A. P. Giannini Foundation (2018)\n\n·Microbiology and Immunology Postdoctoral Fellowship, Stanford School of Medicine (2018)\n\n·Dean's Fellowship, Stanford School of Medicine (2017)\n\n# PROFESSIONAL EDUCATION\n\n·Bachelor of Science, University of Massachusetts Amherst (2009)\n\n·Doctor of Philosophy, California Institute of Technology (2016)\n\n# STANFORD ADVISORS\n\n·Matthew Bogyo, Postdoctoral Faculty Sponsor\n\n# Research & Scholarship\n\n# LAB AFFILIATIONS\n\n·Matthew Bogyo, Bogyo Lab (9/1/2016)\n\n# Publications\n\n# PUBLICATIONS\n\n·Activity-based protein profiling in bacteria: Applications for identification of therapeutic targets and characterization of microbial communities. Current opinion in chemical biology Keller, L. J., Babin, B. M., Lakemeyer, M., Bogyo, M. 2019; 54: 45-53\n\n·Leveraging Peptide Substrate Libraries to Design Inhibitors of Bacterial L on Protease ACS CHEMICAL BIOLOGY", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00011/document_with_boxes.png", "raw_response_path": "sample_00011/raw_response.md", "source_image_path": "sample_00011/source.png", "figures": [{"figure_id": "sample_00011_fig01", "image_path": "sample_00011/figures/sample_00011_fig01.png", "description": "", "image": "sample_00011/figures/sample_00011_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00011_fig01\", \"image_path\": \"sample_00011/figures/sample_00011_fig01.png\", \"description\": \"\"}"]}
-{"sample_id": "sample_00012", "dataset_index": 12, "document_markdown_path": "sample_00012/document.md", "document_markdown_text": "4.4. Graphical view of the workflow generated by the software. The workflow is a graphical view of the workflow generated by the software. The workflow is a graphical view of the workflow generated by the software. The workflow is a graphical view. The workflow is a graphical view. The workflow is a graphical view. The workflow is a graphical view. The workflow is a graphical view. A graphical view of the workflow generated by the software. The workflow is a graphical view. The workflow is a graphical view. The workflow is a graphical overview of the workflow generated by the software. The workflow is a graphical view. The workflow is a graphical view. The workflow is a graphical view. The workflow is a graphical view. The workflow is a graphical overview of the workflow generated by the software. A graphical view of the workflow generated by the software. The workflow is a graphical view. The workflow is a graphical view. The workflow is a graphical view. A graphical view of the workflow generated by the software. The workflow is a graphical view. The workflow is a graphical view. The workflow is an overview of the workflow generated by the software. The workflow is a graphical overview of the workflow generated by the software. The workflow is a graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical view of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. An overview of the workflow generated. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. A graphical overview of the workflow generated by the software. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview. The workflow is a graphical overview", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00012/document_with_boxes.png", "raw_response_path": "sample_00012/raw_response.md", "source_image_path": "sample_00012/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00013", "dataset_index": 13, "document_markdown_path": "sample_00013/document.md", "document_markdown_text": "2019; 14 (11): 2453-62", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00013/document_with_boxes.png", "raw_response_path": "sample_00013/raw_response.md", "source_image_path": "sample_00013/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00014", "dataset_index": 14, "document_markdown_path": "sample_00014/document.md", "document_markdown_text": "4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. \n\nSoftware functionality: SepINRIA has different functionality which can be loaded from a single main window: \n\n- Lesion Segmentation Edition: Manual or semi-automatic segmentation of MS lesions (e.g. a segmentation realized by an expert). Segmentations can be saved and visualized in 2D or 3D. Lesion number and lesion volume can be computed and print. \n\n- Automatic Lesion Segmentation: Automatic segmentation of MS lesions from four MRI sequences (Dual Spin Echo T2-PD, T1, T2-FLAIR). \n\n- Images or Segmentation Comparison: Quantitative comparisons of two images registered to assess evolution and comparison between a segmentation (e.g. automatic segmentation) and a segmentation of reference (segmentation of an expert): by computation of the difference image or by visualizing them in the same window (side to side or image fusion). \n\n- Brain Atrophy Evaluation: Manual and automatic evaluation of the brain atrophy. Linear measurements computation of the brain, lateral ventricle and third ventricle width are available in the manual mode. And evolution of the BPF in function of the exam dates can be perform in the automatic mode. \n\n### 4.2 Structure based on C++ \n\nThis section describes concisely dependencies of the software and also its structure by providing a simplify UML scheme of the code architecture. \n\n#### 4.2.1 Software dependencies \n\nSepINRIA is based on several C++ libraries (C.f. Figure 4.2). ITK and MIPS contain both image processing tools. The first one can be downloaded on Internet and is especially used for image conversion. Whereas the second one is inner to the Asclepios team (algorithms presented in chapter 3 can be found in this library). \n\n\n\n| Parameter* | Adalimumab+MTX
(n=171) | MTX(n=163) |
| \\(Age\\pm \\mathrm {SD}\\)(year) | \\(54.0\\pm 13.1\\) | \\(54.0\\pm 13.2\\) |
| Females (n \\((\\%)\\) | \\(144\\)(84.2) | \\(128\\)(78.5) |
| RA duration±SD (year) | \\(0.3\\pm 0.4\\) | \\(0.3\\pm 0.4\\) |
| Weight±SD (kg) | \\(54.4\\pm 9.7\\) | \\(56.1\\pm 12.3\\) |
| Previous DMARD use (n \\((\\%)\\) | \\(74\\)(43.3) | \\(87\\)(53.4) |
| 1 DMARD | \\(57\\)(33.3) | \\(69\\)(42.3) |
| 2 DMARDs | \\(17\\)(9.9) | \\(18\\)(11.0) |
| Corticosteroid use at baseline (n \\((\\%)\\) | \\(58\\)(33.9) | \\(49\\)(30.1) |
| RF positive (n \\((\\%)\\) | \\(146\\)(85.4) | \\(136\\)(83.4) |
| Mean titre±SD (IU/ml) | \\(154.5\\pm 202.3\\) | \\(163.7\\pm 362.8\\) |
| Anti-CCP positive (n \\((\\%)\\) | \\(145\\)(84.8) | \\(136\\)(83.4) |
| Mean titre±SD (U/ml) | \\(386.2\\pm 694.2\\) | \\(241.3\\pm 367.2\\) |
| ESR (mm/h) | \\(59.9\\pm 30.1\\) | \\(61.8\\pm 29.0\\) |
| CRP (mg/dl) | \\(2.9\\pm 3.0\\) | \\(3.1\\pm 3.3\\) |
| Swollen joint count (n±SD) | | |
| 0-28 | \\(11.5\\pm 4.7\\) | \\(11.8\\pm 5.3\\) |
| 0-66 | \\(16.5\\pm 6.2\\) | \\(17.3\\pm 7.7\\) |
| Tender joint count (n±SD) | | |
| 0-28 | \\(13.2\\pm 5.8\\) | \\(13.2\\pm 6.1\\) |
| 0-68 | \\(20.7\\pm 9.4\\) | \\(21.1\\pm 10.2\\) |
| mTSS | \\(13.6\\pm 22.3\\) | \\(13.6\\pm 17.4\\) |
| Erosion score | \\(7.5\\pm 11.6\\) | \\(7.3\\pm 9.2\\) |
| Joint space narrowing score | \\(6.2\\pm 11.4\\) | \\(6.2\\pm 9.4\\) |
| DAS28-ESR | \\(6.6\\pm 0.9\\) | \\(6.6\\pm 1.0\\) |
| DAS28-CRP | \\(5.8\\pm 1.0\\) | \\(5.9\\pm 1.0\\) |
| HAQ-DI score | \\(1.1\\pm 0.7\\) | \\(1.3\\pm 0.8\\) |
| SDAI score | \\(40.7\\pm 12.0\\) | \\(41.4\\pm 13.8\\) |
| CDAI score | \\(37.8\\pm 10.9\\) | \\(38.3\\pm 12.4\\) |
Physician's global assessment of
disease activity±SD (mm) | \\(65.8\\pm 18.4\\) | \\(66.2\\pm 18.8\\) |
Patient's global assessment of disease
activity±SD (mm) | \\(64.1\\pm 24.8\\) | \\(66.4\\pm 23.7\\) |
\n\n*Data are mean±SD unless otherwise indicated.\n\nCCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.\n\nto 2.2-fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.\n\nA significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 (-0.6±0.6 vs -0.4±0.6; p<0.001). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ-DI score<0.5) after 26 weeks of treatment was also significantly higher with adalimumab+MTX (figure 3F).\n\n# Factors associated with the absence of radiographic progression or with clinical remission\n\nDisease activity or function baseline variables generally were associated with the absence of radiographic progression ( \\(\\Delta \\mathrm {mTSS}\\leq 0.5\\) ) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00018/document_with_boxes.png", "raw_response_path": "sample_00018/raw_response.md", "source_image_path": "sample_00018/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00019", "dataset_index": 19, "document_markdown_path": "sample_00019/document.md", "document_markdown_text": "1 unit\n\n**CPE 101. Fundamentals of Computer Science. 4 units** \nTerm Typically Offered: F, W, SP \nPrerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor. \n\nBasic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101. \n\n**CPE 105. Fundamentals of Computer Science I Supplemental Instruction.** \n\n1 unit \n\nTerm Typically Offered: TBD \nConcurrent: CPE/CSC 101. \n\nFacilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105. \n\nCPE 108. Accelerated Introduction to Computer Science. 4 units \n\nTerm Typically Offered: TBD \nPrerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor. \n\nAccelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108. \n\nCPE 123. Introduction to Computing. 4 units \nTerm Typically Offered: F \nPrerequisite: Basic computer literacy. \n\nUse of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123. \n\nCPE 133. Digital Design. 4 units \nTerm Typically Offered: F, W, SP \nPrerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101. \n\nNumber systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133. \n\nCPE 200. Special Problems for Undergraduates. 1- 2 units \nTerm Typically Offered: F, W, SP \nPrerequisite: Consent of instructor. \n\nIndividual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter. \n\nCPE 202. Data Structures. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor. \n\nIntroduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103. \n\nCPE 203. Project-Based Object-Oriented Programming and Design. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor. \n\nObject-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102. \n\nCPE 233. Computer Design and Assembly Language Programming. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/EE 133. \n\nDesign and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233. \n\nCPE 290. Selected Topics. 1- 4 units \nTerm Typically Offered: TBD \nPrerequisite: Open to undergraduate students and consent of instructor. \n\nDirected group study of selected topics. The Schedule of Classes will list title selected. Total credit limited to 8 units. 1 to 4 lectures.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00019/document_with_boxes.png", "raw_response_path": "sample_00019/raw_response.md", "source_image_path": "sample_00019/source.png", "figures": [], "figures_metadata": []}
{"sample_id": "sample_00020", "dataset_index": 20, "document_markdown_path": "sample_00020/document.md", "document_markdown_text": "1995;38:44-8. 22 Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. 23 Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. 24 Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806. 25 van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. 26 Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60. 27 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13. 28 Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 suppl 39):S100-8.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00020/document_with_boxes.png", "raw_response_path": "sample_00020/raw_response.md", "source_image_path": "sample_00020/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00021", "dataset_index": 21, "document_markdown_path": "sample_00021/document.md", "document_markdown_text": "18-013896 5/9/18;1911 5/9/18;1951 5/7/18;1230 5/7/18;1230 5/11/17;0730 12/1/17;2349 12/1/18;1920 5/11/18;1920 5/11/18;2052 5/12/18;0525 5/12/18;0527 5/12/18;1734 5/12/18;1821 5/13/18;0110 5/13/18;0125 5/13/18;0030 5/13/18;0130 5/13/18;1255 5/14/18;0000 5/15/18;0030 5/16/18;2049 5/16/18;2100 5/16/18;2232 5/16/18;2250 5/16/18;2232- 5/16/18;2250 5/16/18;2322 5/16/18;2250 5/16/18;2250", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00021/document_with_boxes.png", "raw_response_path": "sample_00021/raw_response.md", "source_image_path": "sample_00021/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00022", "dataset_index": 22, "document_markdown_path": "sample_00022/document.md", "document_markdown_text": "1 Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan 2 Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan 3 Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa-ku, Nagoya, Japan 4 Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan 5 Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo-ku, Sapporo, Japan 6 Matsubara Mayflower Hospital, Kato-uchi, Hyogo, Japan 7 Uchida Clinic of Rheumatic Diseases, Sumida-ku, Tokyo, Japan 8 Eisai Co, Ltd., Bunkyo-ku, Tokyo, Japan 9 Abbott GmbH & Co KG, Ludwigshafen, Germany 10 Abbott Laboratories, Abbott Park, Illinois, USA 11 The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi-ku, Kitakyushu, Japan Acknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott. Contributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version. Funding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan). Competing interests TT has received consulting fees, speaking fees, honoraria and/or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra-Zeneca K.K.; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Daiichi-Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol-Myers Squibb; and Otsuka Pharmaceutical Co, and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol-Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co, and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co. NA is an employee of Eisai Co, Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi-Sankyo Co; GlaxoSmithKline K.K.; Astra-Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol-Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K. Patient consent Obtained. Ethics approval An institutional review board approved the study at each site. Provenance and peer review Not commissioned; externally peer reviewed. Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commmercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ References 1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083-90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094-108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75-81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. 5 Smolen JS, Aleatha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor \\(\\alpha\\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMaDalimumab trial. Arthritis Rheum 2003;48:35-45. 9 van de Putte LBA, Atkins C, Malaisie M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644-52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252-62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327-38. 16 Koike T, Hariagi M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498-508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-point counts. Development and validation in a prospective", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00022/document_with_boxes.png", "raw_response_path": "sample_00022/raw_response.md", "source_image_path": "sample_00022/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00023", "dataset_index": 23, "document_markdown_path": "sample_00023/document.md", "document_markdown_text": "0.5cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00023/document_with_boxes.png", "raw_response_path": "sample_00023/raw_response.md", "source_image_path": "sample_00023/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00021", "dataset_index": 21, "document_markdown_path": "sample_00021/document.md", "document_markdown_text": "Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | |
| | | | | | |
", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00021/document_with_boxes.png", "raw_response_path": "sample_00021/raw_response.md", "source_image_path": "sample_00021/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00022", "dataset_index": 22, "document_markdown_path": "sample_00022/document.md", "document_markdown_text": "0.3-0.7 \n\nof anti- TNF- \\(\\alpha\\) and MTX combination therapy in patients with early RA and high disease activity. \n\n## Author affiliations \n\nDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku- ku, Tokyo, Japan Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku- ku, Tokyo, Japan Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa- ku, Nagoya, Japan Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo- ku, Tokyo, Japan Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo- ku, Sapporo, Japan Matsubara Mayflower Hospital, Kato- shi, Hyogo, Japan Uchida Clinic of Rheumatic Diseases, Sumida- ku, Tokyo, Japan Eisai Co, Ltd., Bunkyo- ku, Tokyo, Japan Abbott GmbH & Co KG, Ludwigshafen, Germany Abbott Laboratories, Abbott Park, Illinois, USA The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi- ku, Kitakyushu, Japan \n\nAcknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott. \n\nContributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version. \n\nFunding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan). \n\nCompeting interests TT has received consulting fees, speaking fees, honoraria and/ or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra- Zeneca K.K.; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Daiichi- Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol- Myers Squibb; and Otsuka Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol- Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co; and received compensation for work on this manuscript from Abbott Japan Co. HA is an employee of Eisai Co; Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi- Sankyo Co; GlaxoSmithKline K.K.; Astra- Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol- Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K. \n\npatients other to distribute, remix, adapt, build upon this work non- commercially, \n\nand license their derivative works on different terms, provided the original work is properly cited and the use is non- commercial. See: http://creativecommons.org/licenses/by- nc/3.0/ \n\n## REFERENCES \n\n1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083- 90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094- 108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75- 81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762- 84. 5 Smolen JS, Aletaha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631- 7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26- 37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010;37:2237- 46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti- tumor necrosis factor \\(\\alpha\\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADalimumab trial. Arthritis Rheum 2003;48:35- 45. 9 van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508- 16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti- tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52- week trial. Arthritis Rheum 2004;50:1400- 11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti- tumor necrosis factor- alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563- 71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26- week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64- 71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644- 52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease- affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252- 62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327- 38. 16 Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498- 508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315- 24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in cost see measures, rather than twenty percent? Arthritis Rheum 1998;41:1564- 70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252- 5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00022/document_with_boxes.png", "raw_response_path": "sample_00022/raw_response.md", "source_image_path": "sample_00022/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00023", "dataset_index": 23, "document_markdown_path": "sample_00023/document.md", "document_markdown_text": "0.5cm 0cm 0cm 0cm 0cm \n\n## Adding Time Limit for Degree Completion for Students who Stop Out- \n\nS. Shannon recommended that the addition of a time limit, and listing it in the catalog, for students who leave a program and then return back after years to finish their degrees under their original curriculum. There should be a set time limit as to how long the student can count courses toward the original degree. It was determined that 10 years would be a appropriate time limit. This would close off the option to graduate from their original program if more than 10 years have passed... Motion was approved", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00023/document_with_boxes.png", "raw_response_path": "sample_00023/raw_response.md", "source_image_path": "sample_00023/source.png", "figures": [], "figures_metadata": []}
{"sample_id": "sample_00024", "dataset_index": 24, "document_markdown_path": "sample_00024/document.md", "document_markdown_text": "Local transportation for the participating teams shall be the responsibility of the participating institutions.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00024/document_with_boxes.png", "raw_response_path": "sample_00024/raw_response.md", "source_image_path": "sample_00024/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00025", "dataset_index": 25, "document_markdown_path": "sample_00025/document.md", "document_markdown_text": "5B-10 \n\n| Item | Accounting (based on June 30, 2015 ASC 715 report) | Funding (based on July 1, 2015 valuation report) |
| Service Cost (cost of benefits earned) | N/A - plan frozen | N/A - plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
| Projected Benefit Obligation (PBO) | $15,498,295 | N/A |
| Accumulated Benefit Obligation (ABO)/Funding Target Assets | $15,498,295 | $11,876,067 |
| Balance Sheet Liability | $3,610,049 | $12,025,120 (AVA) |
| AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or curtailment) | $7,690,218 | N/A |
| Cash into Plan | $548,000 (cash basis) | $321,000 (accrual basis) |
| Cash out of Plan | $628,690+$99,236 (expenses) | $628,690+$99,236 (expenses) |
| Liability by Group: | | |
| Actives | $ 4,326,586 | $ 3,046,932 |
| Retired | 6,791,034 | 5,791,017 |
| Terminated Vested | 4,380,675 | 3,038,118 |
| Total | $15,498,295 | $11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
| Demographics: | | |
| Actives | 152 | 152 |
| Retired | 168 | 168 |
| Terminated Vested | 152 | 152 |
| Total | 472 | 472 |
| Discount Rate/Effective Rate | 4.30% (BOY)/4.25% (EOY) | 6.28% |
", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00025/document_with_boxes.png", "raw_response_path": "sample_00025/raw_response.md", "source_image_path": "sample_00025/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00026", "dataset_index": 26, "document_markdown_path": "sample_00026/document.md", "document_markdown_text": "0.00\n\n\n\n# SECTION VI: SCHEDULE OF EVENTS\n\n# Friday\n\nCourse preparation.\n\nCourse walk-through with NCAA site representative.\n\nCourse review and practice by participants.\n\nPacket pick-up.\n\nMandatory coaches meeting.\n\n# Saturday\n\nCourse preparation.\n\nCourse review and practice by participants.\n\nWomen's race - race start time to be determined.*\n\nMen's race - race start time to be determined.*\n\nPost-competition recognition ceremony.\n\n*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00026/document_with_boxes.png", "raw_response_path": "sample_00026/raw_response.md", "source_image_path": "sample_00026/source.png", "figures": [{"figure_id": "sample_00026_fig01", "image_path": "sample_00026/figures/sample_00026_fig01.png", "description": "", "image": "sample_00026/figures/sample_00026_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00026_fig01\", \"image_path\": \"sample_00026/figures/sample_00026_fig01.png\", \"description\": \"\"}"]}
+{"sample_id": "sample_00025", "dataset_index": 25, "document_markdown_path": "sample_00025/document.md", "document_markdown_text": "5B-10\n\n| Item | Accounting (based on June 30,
2015 ASC 715 report) | Funding (based on July 1,2015
valuation report) |
| Service Cost (cost of benefits earned) | N/A-plan frozen | N/A-plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
Projected Benefit Obligation (PBO)
Accumulated Benefit Obligation (ABO)/Funding Target
Assets
Balance Sheet Liability | $15,498,295
$15,498,295
$11,888,246
$3,610,049 | N/A
$11,876,067
$12,025,120 (AVA)
N/A |
AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or
curtailment) | $7,690,218 | N/A |
Cash into Plan
Cash out of Plan | $548,000 (cash basis)
$628,690+$99,236 (expenses) | $321,000 (accrual basis)
$628,690+$99,236 (expenses) |
Liability by Group:
Actives
Retired
Terminated Vested
Total | $ 4,326,586
6,791,034
4,380,675
$15,498,295 | $ 3,046,932
5,791,017
3,038,118
$11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
Demographics:
Actives
Retired
Terminated Vested
Total | 152
168
152
472 | 152
168
152
472 |
| Discount Rate/Effective Rate | 4.30%(BOY)/4.25%(EOY) | 6.28% |
", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00025/document_with_boxes.png", "raw_response_path": "sample_00025/raw_response.md", "source_image_path": "sample_00025/source.png", "figures": [], "figures_metadata": []}
+{"sample_id": "sample_00026", "dataset_index": 26, "document_markdown_path": "sample_00026/document.md", "document_markdown_text": "1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: \n\n## Friday \n\nCourse preparation. Course walk- through with NCAA site representative. Course review and practice by participants. Packet pick- up. Mandatory coaches meeting. \n\n## Saturday \n\nCourse preparation. Course review and practice by participants. Women's race - race start time to be determined.\\* Men's race - race start time to be determined.\\* Post- competition recognition ceremony. \n\n\\*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00026/document_with_boxes.png", "raw_response_path": "sample_00026/raw_response.md", "source_image_path": "sample_00026/source.png", "figures": [], "figures_metadata": []}
{"sample_id": "sample_00027", "dataset_index": 27, "document_markdown_path": "sample_00027/document.md", "document_markdown_text": "5B-6\n\n\n\n* As of July 9, 2015, IRS Notice 2015-49 prohibits sponsors from adopting lump sum windows for participants who currently receive annuity payments.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00027/document_with_boxes.png", "raw_response_path": "sample_00027/raw_response.md", "source_image_path": "sample_00027/source.png", "figures": [{"figure_id": "sample_00027_fig01", "image_path": "sample_00027/figures/sample_00027_fig01.png", "description": "", "image": "sample_00027/figures/sample_00027_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00027_fig01\", \"image_path\": \"sample_00027/figures/sample_00027_fig01.png\", \"description\": \"\"}"]}
-{"sample_id": "sample_00028", "dataset_index": 28, "document_markdown_path": "sample_00028/document.md", "document_markdown_text": "75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales. \n\nThe prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting \"Yes\" below. \n\n \n\nProspective hosts who do not agree with all requirements in this document shall select either \"No\" or \"No with Exception\" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00028/document_with_boxes.png", "raw_response_path": "sample_00028/raw_response.md", "source_image_path": "sample_00028/source.png", "figures": [{"figure_id": "sample_00028_fig01", "image_path": "sample_00028/figures/sample_00028_fig01.png", "description": "", "image": "sample_00028/figures/sample_00028_fig01.png"}], "figures_metadata": ["{\"figure_id\": \"sample_00028_fig01\", \"image_path\": \"sample_00028/figures/sample_00028_fig01.png\", \"description\": \"\"}"]}
+{"sample_id": "sample_00028", "dataset_index": 28, "document_markdown_path": "sample_00028/document.md", "document_markdown_text": "75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales. \n\nThe prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting \"Yes\" below. \n\nProspective hosts who do not agree with all requirements in this document shall select either \"No\" or \"No with Exception\" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00028/document_with_boxes.png", "raw_response_path": "sample_00028/raw_response.md", "source_image_path": "sample_00028/source.png", "figures": [], "figures_metadata": []}
{"sample_id": "sample_00029", "dataset_index": 29, "document_markdown_path": "sample_00029/document.md", "document_markdown_text": "5B-15", "document_final_markdown_path": "", "document_final_markdown_text": "", "document_with_boxes_image_path": "sample_00029/document_with_boxes.png", "raw_response_path": "sample_00029/raw_response.md", "source_image_path": "sample_00029/source.png", "figures": [], "figures_metadata": []}
-{"sample_id": "sample_00030", "dataset_index": 30, "document_markdown_path": "sample_00030/document.md", "document_markdown_text": "145 (Fig. 6B), which over-express EGFR (Fig. 6C). \n\n\n\n| ENGL 3335 | Rhetorical Analysis* |
| FREN 3305 | Introduction to French Literature I* |
| FREN 3306 | Introduction to French Literature II* |
| FREN 4304 | Topics in French Literature of the Eighteenth Century* |
| FREN 4305 | Topics in French Literature of the Nineteenth Century* |
| MUSC 3341 | Music History 1: Ancient Greece to Mozart* |
| MUSC 3342 | Music History 2: Classical Era to the Present* |
| PHIL | All upper division courses** |
| PLSI 3352 | Civil Rights and Liberties |
| PLSI 3361 | Classical Political Thought |
| PSYC 2401 | Statistics and Research Methods |
| PSYC 3451 | Clinical Psychology* |
| RELI 1320 | Ethical Issues in Religious Perspective |
| RELI | All upper division courses* |
| SPAN 3321 | Spanish Cinema* |
\n\nPrinciples of Organizations and Communities\n\n| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122°F (50°C) |
| Altitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical input power | 3 phase from 0 to V supply |
\n\n## AQUAVAR® IPC VARIABLE SPEED CONTROLLER \n\n## FEATURES \n\n- EASIER start-up and programming with Start-Up Genie- Wide range of standard and permanent magnet motors with power up to 600 hp- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)- Remote commissioning and monitoring with USB connectivity and software- Two wire multi-pump connection for faster installation- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation- System redundancy with multi-master control in case of drive failure- BACnet and Modbus as a standard for seamless BMS integration- Submersible and above ground applications- Wide range of voltage and enclosure options- True 208 V coverage- Dedicated single phase input- Remote commissioning and monitoring with USB connectivity and software- In-panel or handheld keypad with backlit display- Alarm Log for last 5 alarms and maintenance events- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference- I/O expansion cards, factory installed or field configured",
+ "document_markdown_text": "0 to 70% (vs. fixed speed) while reducing installation time.\n\n# AQUAVAR® IPC VARIABLE SPEED CONTROLLER \n\n## SPECIFICATIONS \n\n| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50°C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
\n\n## FEATURES \n\n- Easier start-up and programming with Start-Up Genie\n- Wide range of standard and permanent magnet motors with power up to 600 hp\n- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)\n- Remote commissioning and monitoring with USB connectivity and software\n- Two wire multi-pump connection for faster installation\n- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation\n- System redundancy with multi-master control in case of drive failure\n- BACnet and Modbus as a standard for seamless BMS integration\n- Submersible and above ground applications\n- Wide range of voltage and enclosure options\n- True 208 V coverage\n- Dedicated single phase input\n- Remote commissioning and monitoring with USB connectivity and software\n- In-panel or handheld keypad with backlit display\n- Alarm Log for last 5 alarms and maintenance events\n- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference\n- I/O expansion cards, factory installed or field configured",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
- "figures": [
- {
- "figure_id": "sample_00003_fig01",
- "label": "image",
- "image_path": "sample_00003/figures/sample_00003_fig01.png",
- "document_relative_path": "figures/sample_00003_fig01.png",
- "bounding_box_pixels": {
- "x1": 67,
- "y1": 396,
- "x2": 514,
- "y2": 852
- },
- "description": ""
- }
- ]
+ "figures": []
},
{
"sample_id": "sample_00004",
@@ -157,7 +90,7 @@
"raw_response_path": "sample_00004/raw_response.md",
"source_image_path": "sample_00004/source.png",
"document_with_boxes_path": "sample_00004/document_with_boxes.png",
- "document_markdown_text": "2645-9248 Journal homepage: www.jidhealth.com Open A ccess \n\n# A case report on generalized pemphigus vulgaris treated with rituximaba \n\nJ agdish J adavbhai Sakhiya \\(^{1\\ast}\\) , Dhruv J agdish Sakhiya \\(^{1}\\) , J ashmine Mukeshbhai Gandhi \\(^{1}\\) , F eral Ravi Daruwala \\(^{2}\\) \n\n## Abstract \n\nBackground: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris. \n\nCase presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed. \n\nConclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails. \n\nKeywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India \n\n## Background \n\nThe term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus folicaceus (PF). PV is the most common subtype and represents well over \\(80\\%\\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of \n\nimmune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive",
+ "document_markdown_text": "2645-9248 Journal homepage: www.jidhealth.com Open Acess Original Article \n\n# A case report on generalized pemphigus vulgaris treated with rituximaba \n\nJ agdish J adavbhai Sakhiya \\(^{1\\ast}\\) , Dhruv J agdish Sakhiya \\(^{1}\\) , J ashmine Mukeshbhai Gandhi \\(^{1}\\) , Feral Ravi Daruwala \\(^{2}\\) \n\n## Abstract \n\nBackground: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris. \n\nCase presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed. \n\nConclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails. \n\nKeywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India \n\n## Background \n\nThe term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \\(80\\%\\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -169,7 +102,7 @@
"raw_response_path": "sample_00005/raw_response.md",
"source_image_path": "sample_00005/source.png",
"document_with_boxes_path": "sample_00005/document_with_boxes.png",
- "document_markdown_text": "1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine. \n\nInformation Pertinent to Performance of the Procedure \n\n- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).- Patient's ability to lie still for 20-40 min for PET to \\(\\sim 1\\) h for SPECT. \n\n## Precautions and Conscious Sedation \n\n- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients. \n\n## Radiopharmaceutical \n\n## Radiopharmaceutical \n\n- [18F]Fluoro-2-deoxyglucose (FDG). \n- 3-[123I]Iodo-α-methyl-L-tyrosine (IMT). \n- [Methyl-11C]-L-methionine (MET). \n- \\(O-(2-[18F]\\mathrm{Fluoroethyl}) - \\mathrm{L}\\) -tyrosine (FET). \n\n## Recommended Dosage \n\nThe dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode. \n\n- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants. \n- IMT: 100-400 MBq (typically 185 MBq). \n- MET: 200-250 MBq. \n- FET: 200-250 MBq. \n\nThe administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group. \n\n## Radiation Dosimetry (Table 2.1) \n\n## Radiation Dosimetry of Brain Transmission Scans \n\nBased on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \\(\\sim 20 \\mu \\mathrm{Sv}\\) for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.",
+ "document_markdown_text": "1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine. \n\nInformation Pertinent to Performance of the Procedure \n\n- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI). \n\nPrecautions and Conscious Sedation \n\n- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients. \n\nRadiopharmaceutical \n\nRadiopharmaceutical \n\n- [18F]Fluoro-2-deoxyglucose (FDG). \n- 3-\\[^{123}\\mathrm{I}\\]Iodo-α-methyl-L-tyrosine (IMT). \n- \\[ \\mathrm{Methyl-}^{11}\\mathrm{C} \\]-L-methionine (MET). \n- \\(O-(2-[^{18}\\mathrm{F}]\\mathrm{Fluoroethyl})-L\\)-tyrosine (FET). \n\n## Recommended Dosage \n\nThe dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET-cameras with BGO- crystals in 3D- mode. \n\n- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants. \n- IMT: 100-400 MBq (typically 185 MBq). \n- MET: 200-250 MBq. \n- FET: 200-250 MBq. \n\nThe administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group. \n\n## Radiation Dosimetry (Table 2.1) \n\nRadiation Dosimetry of Brain Transmission Scans \n\nBased on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \\(\\sim 20\\) μSv for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -181,24 +114,10 @@
"raw_response_path": "sample_00006/raw_response.md",
"source_image_path": "sample_00006/source.png",
"document_with_boxes_path": "sample_00006/document_with_boxes.png",
- "document_markdown_text": "1? (X) 1? (X) 1? (X) 1? (X) 1? (X) 1? (X) \n\nEntry for the Engineers Ireland Biomedical Research Medal? (X) \n\nPost- Doctoral Researcher/Senior Researcher/PI \n\n## LOAD INDUCED CHANGES IN COLLAGEN FIBRE ARCHITECTURE IN ARTERIES CHARACTERISED BY SMALL ANGLE LIGHT SCATTERING \n\nGaul, R.1,2, Lally, C.1,2 1Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, Ireland. 2School of Engineering, Trinity College Dublin, Dublin, Ireland. email: rgau@tcd.ie \n\n## INTRODUCTION \n\nThe structural strength of arteries is governed by reinforcing collagen fibres present in the vessel wall. Although healthy vessels are capable of fibre remodelling, unhealthy fibre remodelling patterns may be associated with disease [1]. A greater understanding of the remodelling of these fibres may provide greater insight into arteries at risk of disease and how arterial repair may be induced. \n\nSmall angle light scattering (SALS) is a technique which has previously been used to determine the structure of thin, highly organised tissue structures, such as bovine pericardium and porcine aortic valve tissue [2]. \n\nThe aim of the present study is to design and develop a fully automated SALS system capable of determining the changes in arterial fibre architecture in response to strain. \n\n## MATERIALS AND METHODS \n\nAn in- house SALS system has been developed making use of an unpolarised 5mW HeNe laser \\((\\lambda = 632.8 \\text{nm})\\) and two focusing lenses in order to pass light through a tissue sample held in an automated sample positioner. The sample positioner incorporates two stepper motors controlled by LabVIEW to allow movement of the sample in the x and y plane with a resolution of \\(5 \\mu \\text{m}\\) . The sample is interrogated sequentially in \\(250 \\times 250 \\mu \\text{m}\\) regions. The resulting scattered light pattern is recorded by a CMOS camera and analysed through a custom Matlab code to determine predominant collagen fibre directions. \n\nTo validate the system, testing was conducted on test plates with known printed configurations. Once validated, SALS testing was carried out on flat porcine carotid artery wall sections fixed at different stretch ratios. Carotid artery samples were fixed and processed using a standard histological tissue sectioning protocol. Validation of the results was achieved through histological staining of the sections. \n\n## RESULTS \n\nFigure 1a displays the collagen fibre directions in an unstretched carotid artery section, as predicted by SALS, overlaid on picrosirius red stained histological images. Figure 1b shows the reorganisation of the constituent collagen fibres under circumferential stretch \\((\\lambda = 1.25)\\) . \n\nCollagen fibre patterns in the artery were also obtained through the thickness of the artery wall using SALS, for both strained and unstrained configurations. \n\n\n\n| Parameter* | Adalimumab+MTX
(n=171) | MTX(n=163) |
| \\(Age\\pm \\mathrm {SD}\\)(year) | \\(54.0\\pm 13.1\\) | \\(54.0\\pm 13.2\\) |
| Females (n \\((\\%)\\) | \\(144\\)(84.2) | \\(128\\)(78.5) |
| RA duration±SD (year) | \\(0.3\\pm 0.4\\) | \\(0.3\\pm 0.4\\) |
| Weight±SD (kg) | \\(54.4\\pm 9.7\\) | \\(56.1\\pm 12.3\\) |
| Previous DMARD use (n \\((\\%)\\) | \\(74\\)(43.3) | \\(87\\)(53.4) |
| 1 DMARD | \\(57\\)(33.3) | \\(69\\)(42.3) |
| 2 DMARDs | \\(17\\)(9.9) | \\(18\\)(11.0) |
| Corticosteroid use at baseline (n \\((\\%)\\) | \\(58\\)(33.9) | \\(49\\)(30.1) |
| RF positive (n \\((\\%)\\) | \\(146\\)(85.4) | \\(136\\)(83.4) |
| Mean titre±SD (IU/ml) | \\(154.5\\pm 202.3\\) | \\(163.7\\pm 362.8\\) |
| Anti-CCP positive (n \\((\\%)\\) | \\(145\\)(84.8) | \\(136\\)(83.4) |
| Mean titre±SD (U/ml) | \\(386.2\\pm 694.2\\) | \\(241.3\\pm 367.2\\) |
| ESR (mm/h) | \\(59.9\\pm 30.1\\) | \\(61.8\\pm 29.0\\) |
| CRP (mg/dl) | \\(2.9\\pm 3.0\\) | \\(3.1\\pm 3.3\\) |
| Swollen joint count (n±SD) | | |
| 0-28 | \\(11.5\\pm 4.7\\) | \\(11.8\\pm 5.3\\) |
| 0-66 | \\(16.5\\pm 6.2\\) | \\(17.3\\pm 7.7\\) |
| Tender joint count (n±SD) | | |
| 0-28 | \\(13.2\\pm 5.8\\) | \\(13.2\\pm 6.1\\) |
| 0-68 | \\(20.7\\pm 9.4\\) | \\(21.1\\pm 10.2\\) |
| mTSS | \\(13.6\\pm 22.3\\) | \\(13.6\\pm 17.4\\) |
| Erosion score | \\(7.5\\pm 11.6\\) | \\(7.3\\pm 9.2\\) |
| Joint space narrowing score | \\(6.2\\pm 11.4\\) | \\(6.2\\pm 9.4\\) |
| DAS28-ESR | \\(6.6\\pm 0.9\\) | \\(6.6\\pm 1.0\\) |
| DAS28-CRP | \\(5.8\\pm 1.0\\) | \\(5.9\\pm 1.0\\) |
| HAQ-DI score | \\(1.1\\pm 0.7\\) | \\(1.3\\pm 0.8\\) |
| SDAI score | \\(40.7\\pm 12.0\\) | \\(41.4\\pm 13.8\\) |
| CDAI score | \\(37.8\\pm 10.9\\) | \\(38.3\\pm 12.4\\) |
Physician's global assessment of
disease activity±SD (mm) | \\(65.8\\pm 18.4\\) | \\(66.2\\pm 18.8\\) |
Patient's global assessment of disease
activity±SD (mm) | \\(64.1\\pm 24.8\\) | \\(66.4\\pm 23.7\\) |
\n\n*Data are mean±SD unless otherwise indicated.\n\nCCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.\n\nto 2.2-fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.\n\nA significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 (-0.6±0.6 vs -0.4±0.6; p<0.001). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ-DI score<0.5) after 26 weeks of treatment was also significantly higher with adalimumab+MTX (figure 3F).\n\n# Factors associated with the absence of radiographic progression or with clinical remission\n\nDisease activity or function baseline variables generally were associated with the absence of radiographic progression ( \\(\\Delta \\mathrm {mTSS}\\leq 0.5\\) ) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -379,7 +312,7 @@
"raw_response_path": "sample_00019/raw_response.md",
"source_image_path": "sample_00019/source.png",
"document_with_boxes_path": "sample_00019/document_with_boxes.png",
- "document_markdown_text": "1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.\n\n## CPE 101. Fundamentals of Computer Science. 4 units \n\nTerm Typically Offered: F, W, SP Prerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor. \n\nBasic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101. \n\n## CPE 105. Fundamentals of Computer Science I Supplemental Instruction. 1 unit \n\nCR/NC Term Typically Offered: TBD Concurrent: CPE/CSC 101. \n\nFacilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105. \n\n## CPE 108. Accelerated Introduction to Computer Science. 4 units \n\nTerm Typically Offered: TBD Prerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor. \n\nAccelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108. \n\n## CPE 123. Introduction to Computing. 4 units \n\nTerm Typically Offered: F Prerequisite: Basic computer literacy. \n\nUse of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123. \n\n## CPE 133. Digital Design. 4 units \n\nTerm Typically Offered: F,W,SP,SU Prerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101. \n\nNumber systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133. \n\n## CPE 200. Special Problems for Undergraduates. 1-2 units \n\nTerm Typically Offered: F,W,SP,SU Prerequisite: Consent of instructor. \n\nIndividual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter. \n\n## CPE 202. Data Structures. 4 units \n\nTerm Typically Offered: F, W, SP Prerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor. \n\nIntroduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103. \n\n## CPE 203. Project-Based Object-Oriented Programming and Design. 4 units \n\nTerm Typically Offered: F, W, SP Prerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor. \n\nObject-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102. \n\n## CPE 233. Computer Design and Assembly Language Programming. 4 units \n\nTerm Typically Offered: F, W, SP Prerequisite: CPE/EE 133. \n\nDesign and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233. \n\n## CPE 290. Selected Topics. 1-4 units \n\nTerm Typically Offered: TBD \n\nPrerequisite: Open to undergraduate students and consent of instructor. \n\nDirected group study of selected topics. The Schedule of Classes will list title selected. Total credit limited to 8 units. 1 to 4 lectures.",
+ "document_markdown_text": "1 unit\n\n**CPE 101. Fundamentals of Computer Science. 4 units** \nTerm Typically Offered: F, W, SP \nPrerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor. \n\nBasic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101. \n\n**CPE 105. Fundamentals of Computer Science I Supplemental Instruction.** \n\n1 unit \n\nTerm Typically Offered: TBD \nConcurrent: CPE/CSC 101. \n\nFacilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105. \n\nCPE 108. Accelerated Introduction to Computer Science. 4 units \n\nTerm Typically Offered: TBD \nPrerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor. \n\nAccelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108. \n\nCPE 123. Introduction to Computing. 4 units \nTerm Typically Offered: F \nPrerequisite: Basic computer literacy. \n\nUse of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123. \n\nCPE 133. Digital Design. 4 units \nTerm Typically Offered: F, W, SP \nPrerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101. \n\nNumber systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133. \n\nCPE 200. Special Problems for Undergraduates. 1- 2 units \nTerm Typically Offered: F, W, SP \nPrerequisite: Consent of instructor. \n\nIndividual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter. \n\nCPE 202. Data Structures. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor. \n\nIntroduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103. \n\nCPE 203. Project-Based Object-Oriented Programming and Design. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor. \n\nObject-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102. \n\nCPE 233. Computer Design and Assembly Language Programming. 4 units \n\nTerm Typically Offered: F, W, SP \nPrerequisite: CPE/EE 133. \n\nDesign and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233. \n\nCPE 290. Selected Topics. 1- 4 units \nTerm Typically Offered: TBD \nPrerequisite: Open to undergraduate students and consent of instructor. \n\nDirected group study of selected topics. The Schedule of Classes will list title selected. Total credit limited to 8 units. 1 to 4 lectures.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -403,7 +336,7 @@
"raw_response_path": "sample_00021/raw_response.md",
"source_image_path": "sample_00021/source.png",
"document_with_boxes_path": "sample_00021/document_with_boxes.png",
- "document_markdown_text": "18-013896 5/9/18;1911 5/9/18;1951 5/7/18;1230 5/7/18;1230 5/11/17;0730 12/1/17;2349 12/1/18;1920 5/11/18;1920 5/11/18;2052 5/12/18;0525 5/12/18;0527 5/12/18;1734 5/12/18;1821 5/13/18;0110 5/13/18;0125 5/13/18;0030 5/13/18;0130 5/13/18;1255 5/14/18;0000 5/15/18;0030 5/16/18;2049 5/16/18;2100 5/16/18;2232 5/16/18;2250 5/16/18;2232- 5/16/18;2250 5/16/18;2322 5/16/18;2250 5/16/18;2250",
+ "document_markdown_text": "Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | |
| | | | | | |
",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -415,7 +348,7 @@
"raw_response_path": "sample_00022/raw_response.md",
"source_image_path": "sample_00022/source.png",
"document_with_boxes_path": "sample_00022/document_with_boxes.png",
- "document_markdown_text": "1 Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan 2 Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan 3 Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa-ku, Nagoya, Japan 4 Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan 5 Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo-ku, Sapporo, Japan 6 Matsubara Mayflower Hospital, Kato-uchi, Hyogo, Japan 7 Uchida Clinic of Rheumatic Diseases, Sumida-ku, Tokyo, Japan 8 Eisai Co, Ltd., Bunkyo-ku, Tokyo, Japan 9 Abbott GmbH & Co KG, Ludwigshafen, Germany 10 Abbott Laboratories, Abbott Park, Illinois, USA 11 The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi-ku, Kitakyushu, Japan Acknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott. Contributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version. Funding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan). Competing interests TT has received consulting fees, speaking fees, honoraria and/or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra-Zeneca K.K.; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Daiichi-Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol-Myers Squibb; and Otsuka Pharmaceutical Co, and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol-Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co, and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co. NA is an employee of Eisai Co, Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi-Sankyo Co; GlaxoSmithKline K.K.; Astra-Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol-Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K. Patient consent Obtained. Ethics approval An institutional review board approved the study at each site. Provenance and peer review Not commissioned; externally peer reviewed. Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commmercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ References 1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083-90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094-108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75-81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. 5 Smolen JS, Aleatha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor \\(\\alpha\\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMaDalimumab trial. Arthritis Rheum 2003;48:35-45. 9 van de Putte LBA, Atkins C, Malaisie M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644-52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252-62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327-38. 16 Koike T, Hariagi M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498-508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-point counts. Development and validation in a prospective",
+ "document_markdown_text": "0.3-0.7 \n\nof anti- TNF- \\(\\alpha\\) and MTX combination therapy in patients with early RA and high disease activity. \n\n## Author affiliations \n\nDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku- ku, Tokyo, Japan Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku- ku, Tokyo, Japan Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa- ku, Nagoya, Japan Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo- ku, Tokyo, Japan Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo- ku, Sapporo, Japan Matsubara Mayflower Hospital, Kato- shi, Hyogo, Japan Uchida Clinic of Rheumatic Diseases, Sumida- ku, Tokyo, Japan Eisai Co, Ltd., Bunkyo- ku, Tokyo, Japan Abbott GmbH & Co KG, Ludwigshafen, Germany Abbott Laboratories, Abbott Park, Illinois, USA The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi- ku, Kitakyushu, Japan \n\nAcknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott. \n\nContributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version. \n\nFunding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan). \n\nCompeting interests TT has received consulting fees, speaking fees, honoraria and/ or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra- Zeneca K.K.; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Daiichi- Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol- Myers Squibb; and Otsuka Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol- Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co; and received compensation for work on this manuscript from Abbott Japan Co. HA is an employee of Eisai Co; Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi- Sankyo Co; GlaxoSmithKline K.K.; Astra- Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol- Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K. \n\npatients other to distribute, remix, adapt, build upon this work non- commercially, \n\nand license their derivative works on different terms, provided the original work is properly cited and the use is non- commercial. See: http://creativecommons.org/licenses/by- nc/3.0/ \n\n## REFERENCES \n\n1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083- 90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094- 108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75- 81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762- 84. 5 Smolen JS, Aletaha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631- 7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26- 37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010;37:2237- 46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti- tumor necrosis factor \\(\\alpha\\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADalimumab trial. Arthritis Rheum 2003;48:35- 45. 9 van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508- 16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti- tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52- week trial. Arthritis Rheum 2004;50:1400- 11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti- tumor necrosis factor- alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563- 71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26- week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64- 71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644- 52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease- affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252- 62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327- 38. 16 Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498- 508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315- 24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in cost see measures, rather than twenty percent? Arthritis Rheum 1998;41:1564- 70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252- 5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -427,7 +360,7 @@
"raw_response_path": "sample_00023/raw_response.md",
"source_image_path": "sample_00023/source.png",
"document_with_boxes_path": "sample_00023/document_with_boxes.png",
- "document_markdown_text": "0.5cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm",
+ "document_markdown_text": "0.5cm 0cm 0cm 0cm 0cm \n\n## Adding Time Limit for Degree Completion for Students who Stop Out- \n\nS. Shannon recommended that the addition of a time limit, and listing it in the catalog, for students who leave a program and then return back after years to finish their degrees under their original curriculum. There should be a set time limit as to how long the student can count courses toward the original degree. It was determined that 10 years would be a appropriate time limit. This would close off the option to graduate from their original program if more than 10 years have passed... Motion was approved",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -451,7 +384,7 @@
"raw_response_path": "sample_00025/raw_response.md",
"source_image_path": "sample_00025/source.png",
"document_with_boxes_path": "sample_00025/document_with_boxes.png",
- "document_markdown_text": "5B-10 \n\n| Item | Accounting (based on June 30, 2015 ASC 715 report) | Funding (based on July 1, 2015 valuation report) |
| Service Cost (cost of benefits earned) | N/A - plan frozen | N/A - plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
| Projected Benefit Obligation (PBO) | $15,498,295 | N/A |
| Accumulated Benefit Obligation (ABO)/Funding Target Assets | $15,498,295 | $11,876,067 |
| Balance Sheet Liability | $3,610,049 | $12,025,120 (AVA) |
| AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or curtailment) | $7,690,218 | N/A |
| Cash into Plan | $548,000 (cash basis) | $321,000 (accrual basis) |
| Cash out of Plan | $628,690+$99,236 (expenses) | $628,690+$99,236 (expenses) |
| Liability by Group: | | |
| Actives | $ 4,326,586 | $ 3,046,932 |
| Retired | 6,791,034 | 5,791,017 |
| Terminated Vested | 4,380,675 | 3,038,118 |
| Total | $15,498,295 | $11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
| Demographics: | | |
| Actives | 152 | 152 |
| Retired | 168 | 168 |
| Terminated Vested | 152 | 152 |
| Total | 472 | 472 |
| Discount Rate/Effective Rate | 4.30% (BOY)/4.25% (EOY) | 6.28% |
",
+ "document_markdown_text": "5B-10\n\n| Item | Accounting (based on June 30,
2015 ASC 715 report) | Funding (based on July 1,2015
valuation report) |
| Service Cost (cost of benefits earned) | N/A-plan frozen | N/A-plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
Projected Benefit Obligation (PBO)
Accumulated Benefit Obligation (ABO)/Funding Target
Assets
Balance Sheet Liability | $15,498,295
$15,498,295
$11,888,246
$3,610,049 | N/A
$11,876,067
$12,025,120 (AVA)
N/A |
AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or
curtailment) | $7,690,218 | N/A |
Cash into Plan
Cash out of Plan | $548,000 (cash basis)
$628,690+$99,236 (expenses) | $321,000 (accrual basis)
$628,690+$99,236 (expenses) |
Liability by Group:
Actives
Retired
Terminated Vested
Total | $ 4,326,586
6,791,034
4,380,675
$15,498,295 | $ 3,046,932
5,791,017
3,038,118
$11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
Demographics:
Actives
Retired
Terminated Vested
Total | 152
168
152
472 | 152
168
152
472 |
| Discount Rate/Effective Rate | 4.30%(BOY)/4.25%(EOY) | 6.28% |
",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
"figures": []
@@ -463,24 +396,10 @@
"raw_response_path": "sample_00026/raw_response.md",
"source_image_path": "sample_00026/source.png",
"document_with_boxes_path": "sample_00026/document_with_boxes.png",
- "document_markdown_text": "0.00\n\n\n\n# SECTION VI: SCHEDULE OF EVENTS\n\n# Friday\n\nCourse preparation.\n\nCourse walk-through with NCAA site representative.\n\nCourse review and practice by participants.\n\nPacket pick-up.\n\nMandatory coaches meeting.\n\n# Saturday\n\nCourse preparation.\n\nCourse review and practice by participants.\n\nWomen's race - race start time to be determined.*\n\nMen's race - race start time to be determined.*\n\nPost-competition recognition ceremony.\n\n*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.",
+ "document_markdown_text": "1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: \n\n## Friday \n\nCourse preparation. Course walk- through with NCAA site representative. Course review and practice by participants. Packet pick- up. Mandatory coaches meeting. \n\n## Saturday \n\nCourse preparation. Course review and practice by participants. Women's race - race start time to be determined.\\* Men's race - race start time to be determined.\\* Post- competition recognition ceremony. \n\n\\*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
- "figures": [
- {
- "figure_id": "sample_00026_fig01",
- "label": "image",
- "image_path": "sample_00026/figures/sample_00026_fig01.png",
- "document_relative_path": "figures/sample_00026_fig01.png",
- "bounding_box_pixels": {
- "x1": 149,
- "y1": 66,
- "x2": 1121,
- "y2": 317
- },
- "description": ""
- }
- ]
+ "figures": []
},
{
"sample_id": "sample_00027",
@@ -499,10 +418,10 @@
"image_path": "sample_00027/figures/sample_00027_fig01.png",
"document_relative_path": "figures/sample_00027_fig01.png",
"bounding_box_pixels": {
- "x1": 216,
- "y1": 349,
- "x2": 1443,
- "y2": 994
+ "x1": 209,
+ "y1": 348,
+ "x2": 1448,
+ "y2": 998
},
"description": ""
}
@@ -515,24 +434,10 @@
"raw_response_path": "sample_00028/raw_response.md",
"source_image_path": "sample_00028/source.png",
"document_with_boxes_path": "sample_00028/document_with_boxes.png",
- "document_markdown_text": "75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales. \n\nThe prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting \"Yes\" below. \n\n \n\nProspective hosts who do not agree with all requirements in this document shall select either \"No\" or \"No with Exception\" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.",
+ "document_markdown_text": "75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales. \n\nThe prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting \"Yes\" below. \n\nProspective hosts who do not agree with all requirements in this document shall select either \"No\" or \"No with Exception\" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.",
"document_final_markdown_path": "",
"document_final_markdown_text": "",
- "figures": [
- {
- "figure_id": "sample_00028_fig01",
- "label": "image",
- "image_path": "sample_00028/figures/sample_00028_fig01.png",
- "document_relative_path": "figures/sample_00028_fig01.png",
- "bounding_box_pixels": {
- "x1": 399,
- "y1": 1179,
- "x2": 888,
- "y2": 1209
- },
- "description": ""
- }
- ]
+ "figures": []
},
{
"sample_id": "sample_00029",
@@ -553,7 +458,7 @@
"raw_response_path": "sample_00030/raw_response.md",
"source_image_path": "sample_00030/source.png",
"document_with_boxes_path": "sample_00030/document_with_boxes.png",
- "document_markdown_text": "145 (Fig. 6B), which over-express EGFR (Fig. 6C). \n\n\n\n| ENGL 3335 | Rhetorical Analysis* |
| FREN 3305 | Introduction to French Literature I* |
| FREN 3306 | Introduction to French Literature II* |
| FREN 4304 | Topics in French Literature of the Eighteenth Century* |
| FREN 4305 | Topics in French Literature of the Nineteenth Century* |
| MUSC 3341 | Music History 1: Ancient Greece to Mozart* |
| MUSC 3342 | Music History 2: Classical Era to the Present* |
| PHIL | All upper division courses** |
| PLSI 3352 | Civil Rights and Liberties |
| PLSI 3361 | Classical Political Thought |
| PSYC 2401 | Statistics and Research Methods |
| PSYC 3451 | Clinical Psychology* |
| RELI 1320 | Ethical Issues in Religious Perspective |
| RELI | All upper division courses* |
| SPAN 3321 | Spanish Cinema* |
\n\nPrinciples of Organizations and Communities\n\n| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122°F (50°C) |
| Altitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical input power | 3 phase from 0 to V supply |
+| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50°C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
-## AQUAVAR® IPC VARIABLE SPEED CONTROLLER
+## FEATURES
-## FEATURES
-
-- EASIER start-up and programming with Start-Up Genie- Wide range of standard and permanent magnet motors with power up to 600 hp- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)- Remote commissioning and monitoring with USB connectivity and software- Two wire multi-pump connection for faster installation- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation- System redundancy with multi-master control in case of drive failure- BACnet and Modbus as a standard for seamless BMS integration- Submersible and above ground applications- Wide range of voltage and enclosure options- True 208 V coverage- Dedicated single phase input- Remote commissioning and monitoring with USB connectivity and software- In-panel or handheld keypad with backlit display- Alarm Log for last 5 alarms and maintenance events- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference- I/O expansion cards, factory installed or field configured
\ No newline at end of file
+- Easier start-up and programming with Start-Up Genie
+- Wide range of standard and permanent magnet motors with power up to 600 hp
+- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)
+- Remote commissioning and monitoring with USB connectivity and software
+- Two wire multi-pump connection for faster installation
+- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation
+- System redundancy with multi-master control in case of drive failure
+- BACnet and Modbus as a standard for seamless BMS integration
+- Submersible and above ground applications
+- Wide range of voltage and enclosure options
+- True 208 V coverage
+- Dedicated single phase input
+- Remote commissioning and monitoring with USB connectivity and software
+- In-panel or handheld keypad with backlit display
+- Alarm Log for last 5 alarms and maintenance events
+- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference
+- I/O expansion cards, factory installed or field configured
\ No newline at end of file
diff --git a/stage1/sample_00003/document_with_boxes.png b/stage1/sample_00003/document_with_boxes.png
index 57574be60d98d2fd1d8062bdeeeb522746cdddc5..0260fe7ed6c79f91b0926667b8ac06add8cf01a9 100644
--- a/stage1/sample_00003/document_with_boxes.png
+++ b/stage1/sample_00003/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:80c1af1a41bd92a093b6f613cf07685b57cba983017722a6321eb707a00effaa
-size 625805
+oid sha256:bdef21419bf5a9c22e68912f9a6917521b82edca235efbaf663b542e5b8a1832
+size 628816
diff --git a/stage1/sample_00003/raw_response.md b/stage1/sample_00003/raw_response.md
index 5c9fab9523d377fcafacf0a3e351f63617f1b19d..962fedce5f9a97203dea91c1efb54b59c9a5022f 100644
--- a/stage1/sample_00003/raw_response.md
+++ b/stage1/sample_00003/raw_response.md
@@ -1,18 +1,32 @@
-0 to 70% (vs. fixed speed) while reducing installation time.
+0 to 70% (vs. fixed speed) while reducing installation time.
-<|ref|>image<|/ref|><|det|>[[53, 240, 403, 516]]<|/det|>
+<|ref|>title<|/ref|><|det|>[[512, 309, 750, 385]]<|/det|>
+# AQUAVAR® IPC VARIABLE SPEED CONTROLLER
-<|ref|>table<|/ref|><|det|>[[55, 544, 483, 951]]<|/det|>
-<|ref|>table_caption<|/ref|><|det|>[[55, 526, 195, 540]]<|/det|>
-SPECIFICATIONS
+<|ref|>sub_title<|/ref|><|det|>[[55, 528, 198, 542]]<|/det|>
+## SPECIFICATIONS
-| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122°F (50°C) |
| Altitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical input power | 3 phase from 0 to V supply |
+<|ref|>table<|/ref|><|det|>[[56, 547, 486, 950]]<|/det|>
+| Indoor enclosures | IP20 Open, TYPE 1, TYPE 12 |
| Outdoor enclosures | TYPE 3R, TYPE 4X |
| Input supply | 1.5 - 600 hp (frame A - D) wall or base mounted |
| Ambient temperature | 14°F - 113°F (-10°C - 45°C) |
| Communication | Higher temperatures can be achieved by derating the output amperage of the drive 10% for up to 122° F (50°C) |
| Atitudes | Modbus® RTU, Metasys N2, FLN, and BACnet standard
Others available with option cards |
| Relative humidity | At altitudes from 0 to 1,000 meters (0 to 3,300 ft)
Nameplate rated current is available
Derate for altitudes above 1,000 (3,300 ft) with a maximum operating altitude of 3,000 m (9,900 ft)
Consult factory for applications above 3,000 m (9,900 ft) |
| Electrical input power | Lower than 95% without condensation |
| Electrical - output power | 3 phase 380 V to 480 V ±10%
1 phase 200 V to 240 V ±10%
3 phase 200 V to 240 V ±10%
3 phase 525 V to 600 V ±10%
Frequency 50 or 60 Hz, ±2 Hz |
| Electrical - output power | 3 phase from 0 to V supply |
-<|ref|>sub_title<|/ref|><|det|>[[510, 306, 751, 384]]<|/det|>
-## AQUAVAR® IPC VARIABLE SPEED CONTROLLER
+<|ref|>sub_title<|/ref|><|det|>[[512, 433, 597, 448]]<|/det|>
+## FEATURES
-<|ref|>sub_title<|/ref|><|det|>[[511, 431, 596, 445]]<|/det|>
-## FEATURES
-
-<|ref|>text<|/ref|><|det|>[[510, 451, 933, 951]]<|/det|>
-- EASIER start-up and programming with Start-Up Genie- Wide range of standard and permanent magnet motors with power up to 600 hp- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)- Remote commissioning and monitoring with USB connectivity and software- Two wire multi-pump connection for faster installation- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation- System redundancy with multi-master control in case of drive failure- BACnet and Modbus as a standard for seamless BMS integration- Submersible and above ground applications- Wide range of voltage and enclosure options- True 208 V coverage- Dedicated single phase input- Remote commissioning and monitoring with USB connectivity and software- In-panel or handheld keypad with backlit display- Alarm Log for last 5 alarms and maintenance events- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference- I/O expansion cards, factory installed or field configured
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[512, 456, 932, 951]]<|/det|>
+- Easier start-up and programming with Start-Up Genie
+- Wide range of standard and permanent magnet motors with power up to 600 hp
+- Multi-pump configuration for up to four (4) pumps - no need for programmable logic controller (PLC)
+- Remote commissioning and monitoring with USB connectivity and software
+- Two wire multi-pump connection for faster installation
+- Hand on, off, and auto-on buttons available for easy pump operation at the keypad. No toggling between local and remote operation
+- System redundancy with multi-master control in case of drive failure
+- BACnet and Modbus as a standard for seamless BMS integration
+- Submersible and above ground applications
+- Wide range of voltage and enclosure options
+- True 208 V coverage
+- Dedicated single phase input
+- Remote commissioning and monitoring with USB connectivity and software
+- In-panel or handheld keypad with backlit display
+- Alarm Log for last 5 alarms and maintenance events
+- EMC/RFI filters and dual DC-link reactors to reduce drive noise emissions and interference
+- I/O expansion cards, factory installed or field configured
\ No newline at end of file
diff --git a/stage1/sample_00004/document.md b/stage1/sample_00004/document.md
index a198d05f7cda9072d119961842d1feeef3c05b9d..9dba446e6579175b83468a92cef9e8f9de58e179 100644
--- a/stage1/sample_00004/document.md
+++ b/stage1/sample_00004/document.md
@@ -1,8 +1,8 @@
-2645-9248 Journal homepage: www.jidhealth.com Open A ccess
+2645-9248 Journal homepage: www.jidhealth.com Open Acess Original Article
# A case report on generalized pemphigus vulgaris treated with rituximaba
-J agdish J adavbhai Sakhiya \(^{1\ast}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , F eral Ravi Daruwala \(^{2}\)
+J agdish J adavbhai Sakhiya \(^{1\ast}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , Feral Ravi Daruwala \(^{2}\)
## Abstract
@@ -16,6 +16,4 @@ Keywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacc
## Background
-The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus folicaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of
-
-immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive
\ No newline at end of file
+The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive
\ No newline at end of file
diff --git a/stage1/sample_00004/document_with_boxes.png b/stage1/sample_00004/document_with_boxes.png
index ea23e54f6cced3da69da8b37a822559cf7f63f2d..d18f7fab4c19e26775514a953df14e4818865a5d 100644
--- a/stage1/sample_00004/document_with_boxes.png
+++ b/stage1/sample_00004/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:de9e5df909cc7b9d6b012a8d75bdb32a0aebe2641d59a4927373227774dc6379
-size 586833
+oid sha256:14892c4b141d4c727969d7676d7bbbd081e6f1efb6b9cefd17870cd968a7129c
+size 574972
diff --git a/stage1/sample_00004/raw_response.md b/stage1/sample_00004/raw_response.md
index c6e351b9223ef80c84354af8eca0990eb5c7883b..87c38b5f371345ab624e09f19b748d1b03b65ffd 100644
--- a/stage1/sample_00004/raw_response.md
+++ b/stage1/sample_00004/raw_response.md
@@ -1,31 +1,28 @@
-2645-9248 Journal homepage: www.jidhealth.com Open A ccess
+2645-9248 Journal homepage: www.jidhealth.com Open Acess Original Article
-<|ref|>title<|/ref|><|det|>[[88, 217, 794, 266]]<|/det|>
+<|ref|>title<|/ref|><|det|>[[88, 215, 797, 266]]<|/det|>
# A case report on generalized pemphigus vulgaris treated with rituximaba
-<|ref|>text<|/ref|><|det|>[[87, 291, 896, 328]]<|/det|>
-J agdish J adavbhai Sakhiya \(^{1\ast}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , F eral Ravi Daruwala \(^{2}\)
+<|ref|>text<|/ref|><|det|>[[89, 290, 897, 327]]<|/det|>
+J agdish J adavbhai Sakhiya \(^{1\ast}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , Feral Ravi Daruwala \(^{2}\)
-<|ref|>sub_title<|/ref|><|det|>[[102, 351, 175, 365]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[102, 351, 175, 364]]<|/det|>
## Abstract
-<|ref|>text<|/ref|><|det|>[[101, 367, 877, 406]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[100, 366, 876, 406]]<|/det|>
Background: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris.
-<|ref|>text<|/ref|><|det|>[[101, 413, 888, 476]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[100, 412, 890, 477]]<|/det|>
Case presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed.
-<|ref|>text<|/ref|><|det|>[[100, 486, 892, 514]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[100, 486, 890, 514]]<|/det|>
Conclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails.
-<|ref|>text<|/ref|><|det|>[[101, 524, 814, 559]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[100, 523, 814, 558]]<|/det|>
Keywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India
-<|ref|>sub_title<|/ref|><|det|>[[90, 595, 192, 609]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[90, 595, 193, 610]]<|/det|>
## Background
-<|ref|>text<|/ref|><|det|>[[90, 609, 484, 835]]<|/det|>
-The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus folicaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of
-
-<|ref|>text<|/ref|><|det|>[[512, 593, 905, 904]]<|/det|>
-immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[91, 611, 483, 834], [512, 595, 905, 902]]<|/det|>
+The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive
\ No newline at end of file
diff --git a/stage1/sample_00005/document.md b/stage1/sample_00005/document.md
index 7b4d459d8de1fe61f979d23053624cb844087e8f..1328c923582f9683e6bc7dcad9aa4d521052d9b4 100644
--- a/stage1/sample_00005/document.md
+++ b/stage1/sample_00005/document.md
@@ -2,24 +2,24 @@
Information Pertinent to Performance of the Procedure
-- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).- Patient's ability to lie still for 20-40 min for PET to \(\sim 1\) h for SPECT.
+- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).
-## Precautions and Conscious Sedation
+Precautions and Conscious Sedation
- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients.
-## Radiopharmaceutical
+Radiopharmaceutical
-## Radiopharmaceutical
+Radiopharmaceutical
- [18F]Fluoro-2-deoxyglucose (FDG).
-- 3-[123I]Iodo-α-methyl-L-tyrosine (IMT).
-- [Methyl-11C]-L-methionine (MET).
-- \(O-(2-[18F]\mathrm{Fluoroethyl}) - \mathrm{L}\) -tyrosine (FET).
+- 3-\[^{123}\mathrm{I}\]Iodo-α-methyl-L-tyrosine (IMT).
+- \[ \mathrm{Methyl-}^{11}\mathrm{C} \]-L-methionine (MET).
+- \(O-(2-[^{18}\mathrm{F}]\mathrm{Fluoroethyl})-L\)-tyrosine (FET).
## Recommended Dosage
-The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode.
+The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET-cameras with BGO- crystals in 3D- mode.
- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants.
- IMT: 100-400 MBq (typically 185 MBq).
@@ -30,6 +30,6 @@ The administered dose may increase using 2D- mode and vary for other systems acc
## Radiation Dosimetry (Table 2.1)
-## Radiation Dosimetry of Brain Transmission Scans
+Radiation Dosimetry of Brain Transmission Scans
-Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \(\sim 20 \mu \mathrm{Sv}\) for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.
\ No newline at end of file
+Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \(\sim 20\) μSv for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.
\ No newline at end of file
diff --git a/stage1/sample_00005/document_with_boxes.png b/stage1/sample_00005/document_with_boxes.png
index 6dcc55c1562db67d020119f91dc67684bd57d17e..4cf8dbd24c0bc479492e9246eb475c7721f21dbb 100644
--- a/stage1/sample_00005/document_with_boxes.png
+++ b/stage1/sample_00005/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:e32c154f92ccdcb9ac9fdfe69ea29dc2e4bb902966814f043db9a8ec7e41c477
-size 527197
+oid sha256:e85e5cdb4538683931f00a448e29262a5027536e2913c6c853665c8224d7552a
+size 522490
diff --git a/stage1/sample_00005/raw_response.md b/stage1/sample_00005/raw_response.md
index 30aaea69fcb20997e1862bfc6554c65419f3ab54..fce38ecb1d99336969230556fd1096272245a16b 100644
--- a/stage1/sample_00005/raw_response.md
+++ b/stage1/sample_00005/raw_response.md
@@ -1,49 +1,49 @@
1,000 mg given at least 30 min prior to injection) to prevent possible thyroid uptake of free radioactive iodine.
-<|ref|>text<|/ref|><|det|>[[116, 180, 450, 215]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[115, 181, 448, 217]]<|/det|>
Information Pertinent to Performance of the Procedure
-<|ref|>text<|/ref|><|det|>[[115, 224, 493, 475]]<|/det|>
-- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).- Patient's ability to lie still for 20-40 min for PET to \(\sim 1\) h for SPECT.
+<|ref|>text<|/ref|><|det|>[[113, 227, 492, 473]]<|/det|>
+- Patient history with particular focus on previous surgery and/or radiation therapy as well as current and past neurological or psychiatric status.- History of diabetes, fasting state.- Information regarding recent morphological imaging studies (CT, MRI).- Current medication and when last taken, especially psychotropic pharmaceuticals. These may influence regional metabolic rate of glucose (rCMRGI).
-<|ref|>sub_title<|/ref|><|det|>[[116, 498, 439, 515]]<|/det|>
-## Precautions and Conscious Sedation
+<|ref|>text<|/ref|><|det|>[[115, 483, 438, 499]]<|/det|>
+Precautions and Conscious Sedation
-<|ref|>text<|/ref|><|det|>[[115, 527, 492, 897]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[113, 528, 492, 899]]<|/det|>
- Continuous supervision of the patients during the whole scanning procedure is necessary. This is especially important for patients with tumor associated seizures.- In uncooperative patients, it may be worthwhile to apply conscious sedation (e.g., by a short acting benzodiazepine such as i.v., midazolam). For FDG, administration should take place at least 20 min after tracer injection, preferably starting only a few minutes before data acquisition.- Appropriate monitoring (pulse-oximetry) should be performed to recognize the possibility of cardiopulmonary depression and appropriate antidote/emergency backup should be foreseen. Doses of sedation should be reduced in elderly patients.
-<|ref|>sub_title<|/ref|><|det|>[[510, 82, 699, 100]]<|/det|>
-## Radiopharmaceutical
+<|ref|>text<|/ref|><|det|>[[511, 82, 701, 99]]<|/det|>
+Radiopharmaceutical
-<|ref|>sub_title<|/ref|><|det|>[[510, 111, 688, 127]]<|/det|>
-## Radiopharmaceutical
+<|ref|>text<|/ref|><|det|>[[511, 111, 689, 126]]<|/det|>
+Radiopharmaceutical
-<|ref|>text<|/ref|><|det|>[[510, 138, 885, 229]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[511, 137, 886, 227]]<|/det|>
- [18F]Fluoro-2-deoxyglucose (FDG).
-- 3-[123I]Iodo-α-methyl-L-tyrosine (IMT).
-- [Methyl-11C]-L-methionine (MET).
-- \(O-(2-[18F]\mathrm{Fluoroethyl}) - \mathrm{L}\) -tyrosine (FET).
+- 3-\[^{123}\mathrm{I}\]Iodo-α-methyl-L-tyrosine (IMT).
+- \[ \mathrm{Methyl-}^{11}\mathrm{C} \]-L-methionine (MET).
+- \(O-(2-[^{18}\mathrm{F}]\mathrm{Fluoroethyl})-L\)-tyrosine (FET).
-<|ref|>sub_title<|/ref|><|det|>[[510, 259, 696, 276]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[511, 259, 696, 276]]<|/det|>
## Recommended Dosage
-<|ref|>text<|/ref|><|det|>[[509, 286, 886, 361]]<|/det|>
-The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode.
+<|ref|>text<|/ref|><|det|>[[510, 286, 886, 362]]<|/det|>
+The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET-cameras with BGO- crystals in 3D- mode.
-<|ref|>text<|/ref|><|det|>[[509, 364, 886, 507]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[510, 364, 886, 507]]<|/det|>
- FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants.
- IMT: 100-400 MBq (typically 185 MBq).
- MET: 200-250 MBq.
- FET: 200-250 MBq.
-<|ref|>text<|/ref|><|det|>[[509, 520, 886, 692]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[510, 521, 886, 691]]<|/det|>
The administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group.
-<|ref|>sub_title<|/ref|><|det|>[[510, 721, 775, 738]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[511, 722, 775, 739]]<|/det|>
## Radiation Dosimetry (Table 2.1)
-<|ref|>sub_title<|/ref|><|det|>[[510, 748, 866, 783]]<|/det|>
-## Radiation Dosimetry of Brain Transmission Scans
+<|ref|>text<|/ref|><|det|>[[510, 749, 866, 783]]<|/det|>
+Radiation Dosimetry of Brain Transmission Scans
-<|ref|>text<|/ref|><|det|>[[509, 793, 885, 902]]<|/det|>
-Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \(\sim 20 \mu \mathrm{Sv}\) for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[510, 793, 886, 903]]<|/det|>
+Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 μSv for Germanium- based transmission, \(\sim 20\) μSv for low- dose high- speed CT, and between 220 and 450 μSv for high- quality CT.
\ No newline at end of file
diff --git a/stage1/sample_00006/document.md b/stage1/sample_00006/document.md
index 14eda5719148e04b0666637b4cbe745c8bf44590..fdaa937754f00a26c1606f8cdd76e1a699a42acc 100644
--- a/stage1/sample_00006/document.md
+++ b/stage1/sample_00006/document.md
@@ -1,49 +1 @@
-1? (X) 1? (X) 1? (X) 1? (X) 1? (X) 1? (X)
-
-Entry for the Engineers Ireland Biomedical Research Medal? (X)
-
-Post- Doctoral Researcher/Senior Researcher/PI
-
-## LOAD INDUCED CHANGES IN COLLAGEN FIBRE ARCHITECTURE IN ARTERIES CHARACTERISED BY SMALL ANGLE LIGHT SCATTERING
-
-Gaul, R.1,2, Lally, C.1,2 1Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, Ireland. 2School of Engineering, Trinity College Dublin, Dublin, Ireland. email: rgau@tcd.ie
-
-## INTRODUCTION
-
-The structural strength of arteries is governed by reinforcing collagen fibres present in the vessel wall. Although healthy vessels are capable of fibre remodelling, unhealthy fibre remodelling patterns may be associated with disease [1]. A greater understanding of the remodelling of these fibres may provide greater insight into arteries at risk of disease and how arterial repair may be induced.
-
-Small angle light scattering (SALS) is a technique which has previously been used to determine the structure of thin, highly organised tissue structures, such as bovine pericardium and porcine aortic valve tissue [2].
-
-The aim of the present study is to design and develop a fully automated SALS system capable of determining the changes in arterial fibre architecture in response to strain.
-
-## MATERIALS AND METHODS
-
-An in- house SALS system has been developed making use of an unpolarised 5mW HeNe laser \((\lambda = 632.8 \text{nm})\) and two focusing lenses in order to pass light through a tissue sample held in an automated sample positioner. The sample positioner incorporates two stepper motors controlled by LabVIEW to allow movement of the sample in the x and y plane with a resolution of \(5 \mu \text{m}\) . The sample is interrogated sequentially in \(250 \times 250 \mu \text{m}\) regions. The resulting scattered light pattern is recorded by a CMOS camera and analysed through a custom Matlab code to determine predominant collagen fibre directions.
-
-To validate the system, testing was conducted on test plates with known printed configurations. Once validated, SALS testing was carried out on flat porcine carotid artery wall sections fixed at different stretch ratios. Carotid artery samples were fixed and processed using a standard histological tissue sectioning protocol. Validation of the results was achieved through histological staining of the sections.
-
-## RESULTS
-
-Figure 1a displays the collagen fibre directions in an unstretched carotid artery section, as predicted by SALS, overlaid on picrosirius red stained histological images. Figure 1b shows the reorganisation of the constituent collagen fibres under circumferential stretch \((\lambda = 1.25)\) .
-
-Collagen fibre patterns in the artery were also obtained through the thickness of the artery wall using SALS, for both strained and unstrained configurations.
-
-
-
-| Parameter* | Adalimumab+MTX
(n=171) | MTX(n=163) |
| \(Age\pm \mathrm {SD}\)(year) | \(54.0\pm 13.1\) | \(54.0\pm 13.2\) |
| Females (n \((\%)\) | \(144\)(84.2) | \(128\)(78.5) |
| RA duration±SD (year) | \(0.3\pm 0.4\) | \(0.3\pm 0.4\) |
| Weight±SD (kg) | \(54.4\pm 9.7\) | \(56.1\pm 12.3\) |
| Previous DMARD use (n \((\%)\) | \(74\)(43.3) | \(87\)(53.4) |
| 1 DMARD | \(57\)(33.3) | \(69\)(42.3) |
| 2 DMARDs | \(17\)(9.9) | \(18\)(11.0) |
| Corticosteroid use at baseline (n \((\%)\) | \(58\)(33.9) | \(49\)(30.1) |
| RF positive (n \((\%)\) | \(146\)(85.4) | \(136\)(83.4) |
| Mean titre±SD (IU/ml) | \(154.5\pm 202.3\) | \(163.7\pm 362.8\) |
| Anti-CCP positive (n \((\%)\) | \(145\)(84.8) | \(136\)(83.4) |
| Mean titre±SD (U/ml) | \(386.2\pm 694.2\) | \(241.3\pm 367.2\) |
| ESR (mm/h) | \(59.9\pm 30.1\) | \(61.8\pm 29.0\) |
| CRP (mg/dl) | \(2.9\pm 3.0\) | \(3.1\pm 3.3\) |
| Swollen joint count (n±SD) | | |
| 0-28 | \(11.5\pm 4.7\) | \(11.8\pm 5.3\) |
| 0-66 | \(16.5\pm 6.2\) | \(17.3\pm 7.7\) |
| Tender joint count (n±SD) | | |
| 0-28 | \(13.2\pm 5.8\) | \(13.2\pm 6.1\) |
| 0-68 | \(20.7\pm 9.4\) | \(21.1\pm 10.2\) |
| mTSS | \(13.6\pm 22.3\) | \(13.6\pm 17.4\) |
| Erosion score | \(7.5\pm 11.6\) | \(7.3\pm 9.2\) |
| Joint space narrowing score | \(6.2\pm 11.4\) | \(6.2\pm 9.4\) |
| DAS28-ESR | \(6.6\pm 0.9\) | \(6.6\pm 1.0\) |
| DAS28-CRP | \(5.8\pm 1.0\) | \(5.9\pm 1.0\) |
| HAQ-DI score | \(1.1\pm 0.7\) | \(1.3\pm 0.8\) |
| SDAI score | \(40.7\pm 12.0\) | \(41.4\pm 13.8\) |
| CDAI score | \(37.8\pm 10.9\) | \(38.3\pm 12.4\) |
Physician's global assessment of
disease activity±SD (mm) | \(65.8\pm 18.4\) | \(66.2\pm 18.8\) |
Patient's global assessment of disease
activity±SD (mm) | \(64.1\pm 24.8\) | \(66.4\pm 23.7\) |
-\\*Data are mean±SD unless otherwise indicated. CCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.
+*Data are mean±SD unless otherwise indicated.
-to 2.2- fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.
+CCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.
-A significantly larger decrease from baseline in mean HAQ- DI score, indicative of an improvement in physical function, was observed for adalimumab \(+\mathrm {MTX}\) patients versus MTX alone patients at week 26 \((- 0.6\pm 0.6\) vs \(- 0.4\pm 0.6\) ; \(\mathrm {p}<0.001\) ). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ- DI score \(< 0.5\) ) after 26 weeks of treatment was also significantly higher with adalimumab \(+\mathrm {MTX}\) (figure 3F).
+to 2.2-fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.
-## Factors associated with the absence of radiographic progression or with clinical remission
+A significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 (-0.6±0.6 vs -0.4±0.6; p<0.001). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ-DI score<0.5) after 26 weeks of treatment was also significantly higher with adalimumab+MTX (figure 3F).
-Disease activity or function baseline variables generally were associated with the absence of radiographic progression ( \(\Delta \mathrm {mTSS}\leq 0.5\) ) and with clinical remission (DAS28- ESR \(< 2.6\) ) in both treatment groups (see online supplementary text and online supplementary table 1).
\ No newline at end of file
+# Factors associated with the absence of radiographic progression or with clinical remission
+
+Disease activity or function baseline variables generally were associated with the absence of radiographic progression ( \(\Delta \mathrm {mTSS}\leq 0.5\) ) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).
\ No newline at end of file
diff --git a/stage1/sample_00018/document_with_boxes.png b/stage1/sample_00018/document_with_boxes.png
index fb28980ed3bf00868157dcc54e8250eeecfbe99a..ea9880c920d9283573d3e326fad42a75899f7dda 100644
--- a/stage1/sample_00018/document_with_boxes.png
+++ b/stage1/sample_00018/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:29d58e84957eb34227979af901191b1b3658b1954330038e61a6582597dbb08c
-size 810810
+oid sha256:93bea1e1ae62a8bd50237d343dbca978ad6dd5eaa8a4ecb1e203c1d57960c25a
+size 810291
diff --git a/stage1/sample_00018/raw_response.md b/stage1/sample_00018/raw_response.md
index fe8d2531ce4e7b6ddb7a880cfa3eb8a207b8ef1e..7135047876be0c9ecec53fdd6bd1505acfae38a7 100644
--- a/stage1/sample_00018/raw_response.md
+++ b/stage1/sample_00018/raw_response.md
@@ -1,40 +1,44 @@
-24 baseline demographics and disease characteristics. Significant (p<0.1) variables in univariate were included in multivariate models. Last, multivariate models were selected based on model fit statistics (Akaike information criterion and \(\mathbf {r}^{2}\) ) and clinical significance. Adjusted OR and \(95\%\) CIs for selected baseline variables were calculated.
+24 baseline demographics and disease characteristics. Significant (p<0.1) variables in univariate were included in multivariate models. Last, multivariate models were selected based on model fit statistics (Akaike information criterion and \(\mathrm {r}^{2}\)) and clinical significance. Adjusted OR and \(95\%\) CIs for selected baseline variables were calculated.
-<|ref|>sub_title<|/ref|><|det|>[[68, 178, 129, 191]]<|/det|>
-## RESULTS
+<|ref|>title<|/ref|><|det|>[[67, 179, 129, 190]]<|/det|>
+# RESULTS
-<|ref|>text<|/ref|><|det|>[[68, 193, 486, 369]]<|/det|>
-Overall, 334 patients were randomised to treatment and received adalimumab \(+\mathrm {MTX}\) \(\mathrm {n}=171\) )or MTX alone \(\mathrm {n}=163)\) and 148 \(86.5\%)\) and 128 \(78.5\%)\) patients completed the double- blind portion of the study, respectively (figure 1). Demographics and baseline characteristics were well matched between treatment groups (table 1). The mean RA disease duration was 0.3 years, and the majority of patients had \(\geq 1\) erosion at baseline and high disease activity. The mean MTX dose during the 26- week study was \(6.2\pm 0.8\mathrm {mg}/\) week in the adalimumab \(+\mathrm {MTX}\) group and \(6.6\pm 0.6\mathrm {mg}/\) week in the MTX alone group \(\mathrm {p}<0.001\) ). After 26 weeks of treatment, \(34.5\%\) (59/171) of adalimumab \(+\mathrm {MTX}\) patients were receiving MTX 8 mg/week versus \(65.0\%\) (106/163) of MTX alone patients \(\mathrm {p}<0.001\) ).
+<|ref|>text<|/ref|><|det|>[[67, 192, 487, 368]]<|/det|>
+Overall, 334 patients were randomised to treatment and received adalimumab+MTX (n=171) or MTX alone (n=163),and 148 (86.5%) and 128 (78.5%) patients completed the double-blind portion of the study, respectively (figure 1).Demographics and baseline characteristics were well matched between treatment groups (table 1). The mean RA disease duration was 0.3 years, and the majority of patients had \(\geq 1\) erosion at baseline and high disease activity. The mean MTX dose during the 26-week study was \(6.2\pm 0.8\mathrm {mg}/\mathrm {week}\) in the adalimumab+MTX group and \(6.6\pm 0.6\mathrm {mg}/\mathrm {week}\) in the MTX alone group (p<0.001). After 26 weeks of treatment, 34.5%(59/171)of adalimumab+MTX patients were receiving MTX 8 mg/week versus \(65.0\%\) (106/163) of MTX alone patients (p<0.001).
-<|ref|>sub_title<|/ref|><|det|>[[68, 384, 243, 398]]<|/det|>
-## Radiographic progression
+<|ref|>title<|/ref|><|det|>[[67, 385, 242, 397]]<|/det|>
+# Radiographic progression
-<|ref|>text<|/ref|><|det|>[[68, 398, 486, 679]]<|/det|>
-Treatment with adalimumab \(+\mathrm {MTX}\) significantly inhibited radiographic progression (figure 2A) at week 26 versus MTX alone (mean change \(\pm \mathrm {SD}\) , \(1.5\pm 6.1\) vs \(2.4\pm 3.2\) , respectively; \(\mathrm {p}<0.001\) ). Results were confirmed by an LE analysis (figure 2A). Changes in radiographic progression during 26 weeks of treatment were also assessed by a cumulative probability plot of \(\Delta \mathrm {mTSS}\) (figure 2B). Fewer adalimumab \(+\mathrm {MTX}\) patients exhibited radiographic progression \((\Delta \mathrm {mTSS}>0.5)\) ,with \(62.0\%\) (106/171) of patients showing no radiographic progression versus \(35.4\%\) (57/161) of MTX alone patients \(\mathrm {p}<0.001\) ). Furthermore, only \(14.0\%\) (24/171) of adalimumab \(+\mathrm {MTX}\) patients exhibited clinically relevant radiographic progression \((\Delta \mathrm {mTSS}>3)\) versus \(37.3\%\) (60/161) of MTX alone patients \(\mathrm {p}<0.001\) ). In addition, a significantly higher percentage of adalimumab \(+\mathrm {MTX}\) patients did not experience worsening \((\leq 0.5)\) in erosion score ( \(73.7\%\) (126/171)) versus MTX alone patients \(42.2\%\) (68/161); \(\mathrm {p}<0.001\) ). In patients who lacked baseline erosive damage, the continued absence of erosions was reported in more adalimumab \(+\mathrm {MTX}\) patients versus MTX alone patients (9/9 vs 2/6 patients, respectively; \(\mathrm {p}=0.01\) ).
+<|ref|>text<|/ref|><|det|>[[67, 400, 487, 675]]<|/det|>
+Treatment with adalimumab+MTX significantly inhibited radiographic progression (figure 2A) at week 26 versus MTX alone (mean change±SD, \(1.5\pm 6.1\) vs \(2.4\pm 3.2\) respectively;p<0.001). Results were confirmed by an LE analysis (figure 2A). Changes in radiographic progression during 26 weeks of treatment were also assessed by a cumulative probability plot of \(\Delta \mathrm {mTSS}\) (figure 2B). Fewer adalimumab+MTX patients exhibited radiographic progression \((\Delta \mathrm {mTSS}>0.5)\) with \(62.0\%\) (106/171) of patients showing no radiographic progression versus 35.4%(57/161) of MTX alone patients (p<0.001).Furthermore, only 14.0%(24/171) of adalimumab+MTX patients exhibited clinically relevant radiographic progression \((\Delta \mathrm {mTSS}>3)\) versus 37.3%(60/161) of MTX alone patients (p<0.001). In addition, a significantly higher percentage of adalimumab+MTX patients did not experience worsening \((\leq 0.5)\) in erosion score (73.7%(126/171)) versus MTX alone patients (42.2%(68/161);p<0.001). In patients who lacked baseline erosive damage, the continued absence of erosions was reported in more adalimumab+MTX patients versus MTX alone patients (9/9 vs 2/6 patients, respectively; p=0.01).
-<|ref|>sub_title<|/ref|><|det|>[[68, 693, 181, 707]]<|/det|>
-## Clinical response
+<|ref|>title<|/ref|><|det|>[[67, 693, 187, 705]]<|/det|>
+# Clinical response
-<|ref|>text<|/ref|><|det|>[[68, 707, 486, 951]]<|/det|>
-A significantly higher percentage of adalimumab \(+\mathrm {MTX}\) patients achieved ACR responses versus MTX alone patients at each assessment (figure 3A- C). Significant differences between treatment groups, observed as early as week 2, were maintained through week 26. At week 26, a significantly larger percentage of adalimumab \(+\mathrm {MTX}\) patients versus MTX alone patients achieved ACR20, ACR50 and ACR70 (figure 3A- C) and ACR90 ( \(12.9\%\) vs \(5.5\%\) ; \(\mathrm {p}=0.02\) ) responses. Significant differences in favour of adalimumab \(+\mathrm {MTX}\) were also observed from week 2 to 26 for DAS28- ESR, DAS28- CRP, SDAI and CDAI (see online supplementary figure 1A- D). A larger percentage of adalimumab \(+\mathrm {MTX}\) patients than MTX alone patients demonstrated good or moderate European League Against Rheumatism responses (figure 3D) and were in states of low disease activity or remission after 26 weeks of treatment (figure 3E). Furthermore, a significantly larger percentage of adalimumab \(+\mathrm {MTX}\) patients versus MTX alone patients satisfied Boolean remission criteria \(19.3\%\) vs \(8.6\%\) , \(\mathrm {p}=0.007\) ). Adalimumab \(+\mathrm {MTX}\) achieved a 1.8-
+<|ref|>text<|/ref|><|det|>[[67, 707, 487, 950], [519, 677, 929, 718]]<|/det|>
+A significantly higher percentage of adalimumab+MTX patients achieved ACR responses versus MTX alone patients at each assessment (figure 3A-C). Significant differences between treatment groups, observed as early as week 2, were maintained through week 26. At week 26, a significantly larger percentage of adalimumab+MTX patients versus MTX alone patients achieved ACR20, ACR50 and ACR70 (figure 3A-C) and ACR90 (12.9% vs 5.5%; p=0.02) responses. Significant differences in favour of adalimumab+MTX were also observed from week 2 to 26 for DAS28-ESR, DAS28-CRP, SDAI and CDAI (see online supplementary figure 1A-D). A larger percentage of adalimumab+MTX patients than MTX alone patients demonstrated good or moderate European League Against Rheumatism responses (figure 3D) and were in states of low disease activity or remission after 26 weeks of treatment (figure 3E). Furthermore, a significantly larger percentage of adalimumab+MTX patients versus MTX alone patients satisfied Boolean remission criteria (19.3% vs 8.6%, p=0.007). Adalimumab+MTX achieved a 1.8-to 2.2-fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.
-<|ref|>table<|/ref|><|det|>[[519, 92, 918, 568]]<|/det|>
-<|ref|>table_caption<|/ref|><|det|>[[522, 74, 828, 89]]<|/det|>
-Table 1 Demographics and baseline characteristics
+<|ref|>table_caption<|/ref|><|det|>[[519, 74, 827, 87]]<|/det|>
+Table 1 Demographics and baseline characteristics
-| Parameter* | Adalimumab+MTX
(n=171) | MTX(n=163) |
| \(Age\pm \mathrm {SD}\)(year) | \(54.0\pm 13.1\) | \(54.0\pm 13.2\) |
| Females (n \((\%)\) | \(144\)(84.2) | \(128\)(78.5) |
| RA duration±SD (year) | \(0.3\pm 0.4\) | \(0.3\pm 0.4\) |
| Weight±SD (kg) | \(54.4\pm 9.7\) | \(56.1\pm 12.3\) |
| Previous DMARD use (n \((\%)\) | \(74\)(43.3) | \(87\)(53.4) |
| 1 DMARD | \(57\)(33.3) | \(69\)(42.3) |
| 2 DMARDs | \(17\)(9.9) | \(18\)(11.0) |
| Corticosteroid use at baseline (n \((\%)\) | \(58\)(33.9) | \(49\)(30.1) |
| RF positive (n \((\%)\) | \(146\)(85.4) | \(136\)(83.4) |
| Mean titre±SD (IU/ml) | \(154.5\pm 202.3\) | \(163.7\pm 362.8\) |
| Anti-CCP positive (n \((\%)\) | \(145\)(84.8) | \(136\)(83.4) |
| Mean titre±SD (U/ml) | \(386.2\pm 694.2\) | \(241.3\pm 367.2\) |
| ESR (mm/h) | \(59.9\pm 30.1\) | \(61.8\pm 29.0\) |
| CRP (mg/dl) | \(2.9\pm 3.0\) | \(3.1\pm 3.3\) |
| Swollen joint count (n±SD) | | |
| 0-28 | \(11.5\pm 4.7\) | \(11.8\pm 5.3\) |
| 0-66 | \(16.5\pm 6.2\) | \(17.3\pm 7.7\) |
| Tender joint count (n±SD) | | |
| 0-28 | \(13.2\pm 5.8\) | \(13.2\pm 6.1\) |
| 0-68 | \(20.7\pm 9.4\) | \(21.1\pm 10.2\) |
| mTSS | \(13.6\pm 22.3\) | \(13.6\pm 17.4\) |
| Erosion score | \(7.5\pm 11.6\) | \(7.3\pm 9.2\) |
| Joint space narrowing score | \(6.2\pm 11.4\) | \(6.2\pm 9.4\) |
| DAS28-ESR | \(6.6\pm 0.9\) | \(6.6\pm 1.0\) |
| DAS28-CRP | \(5.8\pm 1.0\) | \(5.9\pm 1.0\) |
| HAQ-DI score | \(1.1\pm 0.7\) | \(1.3\pm 0.8\) |
| SDAI score | \(40.7\pm 12.0\) | \(41.4\pm 13.8\) |
| CDAI score | \(37.8\pm 10.9\) | \(38.3\pm 12.4\) |
Physician's global assessment of
disease activity±SD (mm) | \(65.8\pm 18.4\) | \(66.2\pm 18.8\) |
Patient's global assessment of disease
activity±SD (mm) | \(64.1\pm 24.8\) | \(66.4\pm 23.7\) |
-<|ref|>text<|/ref|><|det|>[[519, 679, 927, 721]]<|/det|>
-to 2.2- fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.
+<|ref|>text<|/ref|><|det|>[[519, 569, 742, 579]]<|/det|>
+*Data are mean±SD unless otherwise indicated.
-<|ref|>text<|/ref|><|det|>[[519, 722, 927, 828]]<|/det|>
-A significantly larger decrease from baseline in mean HAQ- DI score, indicative of an improvement in physical function, was observed for adalimumab \(+\mathrm {MTX}\) patients versus MTX alone patients at week 26 \((- 0.6\pm 0.6\) vs \(- 0.4\pm 0.6\) ; \(\mathrm {p}<0.001\) ). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ- DI score \(< 0.5\) ) after 26 weeks of treatment was also significantly higher with adalimumab \(+\mathrm {MTX}\) (figure 3F).
+<|ref|>text<|/ref|><|det|>[[519, 580, 919, 654]]<|/det|>
+CCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.
-<|ref|>sub_title<|/ref|><|det|>[[519, 858, 862, 885]]<|/det|>
-## Factors associated with the absence of radiographic progression or with clinical remission
+<|ref|>text<|/ref|><|det|>[[512, 679, 929, 721]]<|/det|>
+to 2.2-fold increase in the percentage of patients achieving clinical remission, across all definitions of clinical remission evaluated, versus MTX alone.
-<|ref|>text<|/ref|><|det|>[[519, 885, 927, 952]]<|/det|>
-Disease activity or function baseline variables generally were associated with the absence of radiographic progression ( \(\Delta \mathrm {mTSS}\leq 0.5\) ) and with clinical remission (DAS28- ESR \(< 2.6\) ) in both treatment groups (see online supplementary text and online supplementary table 1).
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[512, 723, 929, 828]]<|/det|>
+A significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 (-0.6±0.6 vs -0.4±0.6; p<0.001). Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functionality (HAQ-DI score<0.5) after 26 weeks of treatment was also significantly higher with adalimumab+MTX (figure 3F).
+
+<|ref|>title<|/ref|><|det|>[[512, 856, 862, 883]]<|/det|>
+# Factors associated with the absence of radiographic progression or with clinical remission
+
+<|ref|>text<|/ref|><|det|>[[512, 885, 929, 952]]<|/det|>
+Disease activity or function baseline variables generally were associated with the absence of radiographic progression ( \(\Delta \mathrm {mTSS}\leq 0.5\) ) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).
\ No newline at end of file
diff --git a/stage1/sample_00019/document.md b/stage1/sample_00019/document.md
index 321bffa1175e827d8e50c9effda6c678980c8647..d8aa5d9c240b7e8e1f95d1d124f5f4f1791df2ef 100644
--- a/stage1/sample_00019/document.md
+++ b/stage1/sample_00019/document.md
@@ -1,63 +1,68 @@
-1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.
+1 unit
-## CPE 101. Fundamentals of Computer Science. 4 units
+**CPE 101. Fundamentals of Computer Science. 4 units**
+Term Typically Offered: F, W, SP
+Prerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor.
-Term Typically Offered: F, W, SP Prerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor.
+Basic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101.
-Basic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101.
+**CPE 105. Fundamentals of Computer Science I Supplemental Instruction.**
-## CPE 105. Fundamentals of Computer Science I Supplemental Instruction. 1 unit
+1 unit
-CR/NC Term Typically Offered: TBD Concurrent: CPE/CSC 101.
+Term Typically Offered: TBD
+Concurrent: CPE/CSC 101.
-Facilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105.
+Facilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105.
-## CPE 108. Accelerated Introduction to Computer Science. 4 units
+CPE 108. Accelerated Introduction to Computer Science. 4 units
-Term Typically Offered: TBD Prerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor.
+Term Typically Offered: TBD
+Prerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor.
-Accelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108.
+Accelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108.
-## CPE 123. Introduction to Computing. 4 units
+CPE 123. Introduction to Computing. 4 units
+Term Typically Offered: F
+Prerequisite: Basic computer literacy.
-Term Typically Offered: F Prerequisite: Basic computer literacy.
+Use of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123.
-Use of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123.
+CPE 133. Digital Design. 4 units
+Term Typically Offered: F, W, SP
+Prerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101.
-## CPE 133. Digital Design. 4 units
+Number systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133.
-Term Typically Offered: F,W,SP,SU Prerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101.
+CPE 200. Special Problems for Undergraduates. 1- 2 units
+Term Typically Offered: F, W, SP
+Prerequisite: Consent of instructor.
-Number systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133.
+Individual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter.
-## CPE 200. Special Problems for Undergraduates. 1-2 units
+CPE 202. Data Structures. 4 units
-Term Typically Offered: F,W,SP,SU Prerequisite: Consent of instructor.
+Term Typically Offered: F, W, SP
+Prerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor.
-Individual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter.
+Introduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103.
-## CPE 202. Data Structures. 4 units
+CPE 203. Project-Based Object-Oriented Programming and Design. 4 units
-Term Typically Offered: F, W, SP Prerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor.
+Term Typically Offered: F, W, SP
+Prerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor.
-Introduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103.
+Object-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102.
-## CPE 203. Project-Based Object-Oriented Programming and Design. 4 units
+CPE 233. Computer Design and Assembly Language Programming. 4 units
-Term Typically Offered: F, W, SP Prerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor.
+Term Typically Offered: F, W, SP
+Prerequisite: CPE/EE 133.
-Object-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102.
+Design and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233.
-## CPE 233. Computer Design and Assembly Language Programming. 4 units
-
-Term Typically Offered: F, W, SP Prerequisite: CPE/EE 133.
-
-Design and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233.
-
-## CPE 290. Selected Topics. 1-4 units
-
-Term Typically Offered: TBD
-
-Prerequisite: Open to undergraduate students and consent of instructor.
+CPE 290. Selected Topics. 1- 4 units
+Term Typically Offered: TBD
+Prerequisite: Open to undergraduate students and consent of instructor.
Directed group study of selected topics. The Schedule of Classes will list title selected. Total credit limited to 8 units. 1 to 4 lectures.
\ No newline at end of file
diff --git a/stage1/sample_00019/document_with_boxes.png b/stage1/sample_00019/document_with_boxes.png
index 971c4bcefe3153e5c417da06eb5186fa0c167e2c..b12a3fa14866cc8b329e350290951472600760e7 100644
--- a/stage1/sample_00019/document_with_boxes.png
+++ b/stage1/sample_00019/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:3d72af8edd48c37f450acd7e3c26163ad21d5a249aa477748fcd5495c55a8ff2
-size 583493
+oid sha256:edb71029fc214303af8d56c1e97d11570fc84eff29d4ff7acbcfaa8896fa8563
+size 581477
diff --git a/stage1/sample_00019/raw_response.md b/stage1/sample_00019/raw_response.md
index 5921b2afc6cc6ebfcab6f94b259ab48e19e60684..92f637b4a543f06ddda6b3c442a3a485f6ad3471 100644
--- a/stage1/sample_00019/raw_response.md
+++ b/stage1/sample_00019/raw_response.md
@@ -1,94 +1,94 @@
-1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.
+1 unit
-<|ref|>sub_title<|/ref|><|det|>[[56, 93, 372, 105]]<|/det|>
-## CPE 101. Fundamentals of Computer Science. 4 units
+<|ref|>text<|/ref|><|det|>[[56, 90, 488, 156]]<|/det|>
+**CPE 101. Fundamentals of Computer Science. 4 units**
+Term Typically Offered: F, W, SP
+Prerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor.
-<|ref|>text<|/ref|><|det|>[[56, 107, 488, 157]]<|/det|>
-Term Typically Offered: F, W, SP Prerequisite: Completion of ELM requirement, and passing score on MAPE or MATH 117 with a grade of C- or better or MATH 118 with a grade of C- or better, or consent of instructor.
+<|ref|>text<|/ref|><|det|>[[56, 168, 490, 275]]<|/det|>
+Basic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101.
-<|ref|>text<|/ref|><|det|>[[56, 169, 487, 278]]<|/det|>
-Basic principles of algorithmic problem solving and programming using methods of top-down design, stepwise refinement and procedural abstraction. Basic control structures, data types, and input/output. Introduction to the software development process: design, implementation, testing and documentation. The syntax and semantics of a modern programming language. Credit not available for students who have taken CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 101.
+<|ref|>text<|/ref|><|det|>[[56, 289, 488, 313]]<|/det|>
+**CPE 105. Fundamentals of Computer Science I Supplemental Instruction.**
-<|ref|>sub_title<|/ref|><|det|>[[56, 290, 487, 316]]<|/det|>
-## CPE 105. Fundamentals of Computer Science I Supplemental Instruction. 1 unit
+<|ref|>text<|/ref|><|det|>[[56, 315, 99, 339]]<|/det|>
+1 unit
-<|ref|>text<|/ref|><|det|>[[56, 318, 220, 358]]<|/det|>
-CR/NC Term Typically Offered: TBD Concurrent: CPE/CSC 101.
+<|ref|>text<|/ref|><|det|>[[56, 341, 222, 366]]<|/det|>
+Term Typically Offered: TBD
+Concurrent: CPE/CSC 101.
-<|ref|>text<|/ref|><|det|>[[56, 370, 476, 409]]<|/det|>
-Facilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105.
+<|ref|>text<|/ref|><|det|>[[56, 373, 476, 414]]<|/det|>
+Facilitated study and discussion of fundamental concepts of computer science and familiarization with programming environments. Credit/No Credit grading only. 1 laboratory. Crosslisted as CPE/CSC 105.
-<|ref|>sub_title<|/ref|><|det|>[[56, 421, 433, 433]]<|/det|>
-## CPE 108. Accelerated Introduction to Computer Science. 4 units
+<|ref|>text<|/ref|><|det|>[[56, 423, 435, 438]]<|/det|>
+CPE 108. Accelerated Introduction to Computer Science. 4 units
-<|ref|>text<|/ref|><|det|>[[56, 436, 450, 489]]<|/det|>
-Term Typically Offered: TBD Prerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor.
+<|ref|>text<|/ref|><|det|>[[56, 439, 447, 492]]<|/det|>
+Term Typically Offered: TBD
+Prerequisite: MATH 118 (or equivalent) with a grade of C- or better, significant experience in computer programming, and consent of instructor.
-<|ref|>text<|/ref|><|det|>[[56, 501, 488, 637]]<|/det|>
-Accelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108.
+<|ref|>text<|/ref|><|det|>[[56, 502, 490, 638]]<|/det|>
+Accelerated introduction to basic principles of algorithmic and object-oriented problem solving and programming. Introduction to programming language concepts including control structures, data types, classes, and inheritance. Program design principles. Use and implementation of algorithms (searching, sorting, recursion) and data structures (lists, stacks, and queues). Intended for students with experience in algorithmic problem solving and using basic control structures and data types in a modern programming language (CPE/CSC 101), but who are not ready for CPE/CSC 202. Not open to students with credit in CPE/CSC 102 or CPE/CSC 202. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 108.
-<|ref|>sub_title<|/ref|><|det|>[[56, 649, 318, 661]]<|/det|>
-## CPE 123. Introduction to Computing. 4 units
+<|ref|>text<|/ref|><|det|>[[56, 651, 320, 691]]<|/det|>
+CPE 123. Introduction to Computing. 4 units
+Term Typically Offered: F
+Prerequisite: Basic computer literacy.
-<|ref|>text<|/ref|><|det|>[[56, 663, 277, 689]]<|/det|>
-Term Typically Offered: F Prerequisite: Basic computer literacy.
+<|ref|>text<|/ref|><|det|>[[56, 703, 473, 796]]<|/det|>
+Use of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123.
-<|ref|>text<|/ref|><|det|>[[56, 702, 473, 797]]<|/det|>
-Use of a supportive software development environment to design, develop, and test applications in a selected topic domain that demonstrates the potential of careers in computing. An introduction to computing and to the selected topic domain. The Schedule of Classes will list topic selected. No programming experience required. Not for students with credit in CPE/CSC 103 or CPE/CSC 203. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 123.
+<|ref|>text<|/ref|><|det|>[[506, 91, 926, 144]]<|/det|>
+CPE 133. Digital Design. 4 units
+Term Typically Offered: F, W, SP
+Prerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101.
-<|ref|>sub_title<|/ref|><|det|>[[506, 93, 693, 105]]<|/det|>
-## CPE 133. Digital Design. 4 units
+<|ref|>text<|/ref|><|det|>[[506, 156, 937, 250]]<|/det|>
+Number systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133.
-<|ref|>text<|/ref|><|det|>[[506, 108, 920, 134]]<|/det|>
-Term Typically Offered: F,W,SP,SU Prerequisite: An orientation course in student's major (EE 111 & EE 151 for EE students, CPE 100 for CPE students), CPE/CSC 101.
+<|ref|>text<|/ref|><|det|>[[506, 262, 847, 301]]<|/det|>
+CPE 200. Special Problems for Undergraduates. 1- 2 units
+Term Typically Offered: F, W, SP
+Prerequisite: Consent of instructor.
-<|ref|>text<|/ref|><|det|>[[506, 151, 936, 250]]<|/det|>
-Number systems, Boolean algebra, Boolean functions, and function minimization. Analysis and design of combinational and sequential logic circuits. Hardware Description Language (HDL) concepts and applications digital design and synthesis in Programmable Logic Devices (PLDs). Not open to students with credit in CPE/EE 129. Course may be offered in classroom-based or online format. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 133.
+<|ref|>text<|/ref|><|det|>[[506, 313, 927, 355]]<|/det|>
+Individual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter.
-<|ref|>sub_title<|/ref|><|det|>[[506, 263, 846, 275]]<|/det|>
-## CPE 200. Special Problems for Undergraduates. 1-2 units
+<|ref|>text<|/ref|><|det|>[[506, 368, 706, 381]]<|/det|>
+CPE 202. Data Structures. 4 units
-<|ref|>text<|/ref|><|det|>[[506, 278, 714, 303]]<|/det|>
-Term Typically Offered: F,W,SP,SU Prerequisite: Consent of instructor.
+<|ref|>text<|/ref|><|det|>[[506, 383, 908, 422]]<|/det|>
+Term Typically Offered: F, W, SP
+Prerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor.
-<|ref|>text<|/ref|><|det|>[[506, 315, 924, 354]]<|/det|>
-Individual investigation, research, studies, or surveys of selected problems. Total credit limited to 4 units, with a maximum of 2 units per quarter.
+<|ref|>text<|/ref|><|det|>[[506, 434, 936, 514]]<|/det|>
+Introduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103.
-<|ref|>sub_title<|/ref|><|det|>[[506, 367, 704, 379]]<|/det|>
-## CPE 202. Data Structures. 4 units
+<|ref|>text<|/ref|><|det|>[[506, 526, 912, 550]]<|/det|>
+CPE 203. Project-Based Object-Oriented Programming and Design. 4 units
-<|ref|>text<|/ref|><|det|>[[506, 381, 905, 420]]<|/det|>
-Term Typically Offered: F, W, SP Prerequisite: CPE/CSC 101 with a grade of C- or better; MATH 141 or MATH 221 with a grade of C- or better; or consent of instructor.
+<|ref|>text<|/ref|><|det|>[[506, 552, 908, 593]]<|/det|>
+Term Typically Offered: F, W, SP
+Prerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor.
-<|ref|>text<|/ref|><|det|>[[506, 433, 935, 511]]<|/det|>
-Introduction to data structures and analysis of algorithms. Abstract datatypes. Specification and implementation of advanced data structures. Theoretical and empirical analysis of recursive and iterative algorithms. Software performance evaluation and testing techniques. Not open to students with credit in CSC/CPE 108. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 202. Formerly CPE/CSC 103.
+<|ref|>text<|/ref|><|det|>[[506, 605, 913, 659]]<|/det|>
+Object-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102.
-<|ref|>sub_title<|/ref|><|det|>[[506, 523, 912, 548]]<|/det|>
-## CPE 203. Project-Based Object-Oriented Programming and Design. 4 units
+<|ref|>text<|/ref|><|det|>[[506, 671, 911, 683]]<|/det|>
+CPE 233. Computer Design and Assembly Language Programming. 4 units
-<|ref|>text<|/ref|><|det|>[[506, 551, 905, 590]]<|/det|>
-Term Typically Offered: F, W, SP Prerequisite: CPE/CSC 202 with a grade of C- or better or consent of instructor.
+<|ref|>text<|/ref|><|det|>[[506, 687, 695, 730]]<|/det|>
+Term Typically Offered: F, W, SP
+Prerequisite: CPE/EE 133.
-<|ref|>text<|/ref|><|det|>[[506, 604, 911, 655]]<|/det|>
-Object-oriented programming and design with applications to project construction. Introduction to class design, interfaces, inheritance, generics, exceptions, streams, and testing. 3 lectures, 1 laboratory. Crosslisted as CPE/CSC 203. Formerly CPE/CSC 102.
+<|ref|>text<|/ref|><|det|>[[506, 742, 932, 814]]<|/det|>
+Design and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233.
-<|ref|>sub_title<|/ref|><|det|>[[506, 669, 912, 694]]<|/det|>
-## CPE 233. Computer Design and Assembly Language Programming. 4 units
+<|ref|>text<|/ref|><|det|>[[506, 827, 933, 853]]<|/det|>
+CPE 290. Selected Topics. 1- 4 units
+Term Typically Offered: TBD
+Prerequisite: Open to undergraduate students and consent of instructor.
-<|ref|>text<|/ref|><|det|>[[506, 697, 695, 724]]<|/det|>
-Term Typically Offered: F, W, SP Prerequisite: CPE/EE 133.
-
-<|ref|>text<|/ref|><|det|>[[506, 739, 929, 817]]<|/det|>
-Design and implementation of digital computer circuits via CAD tools for programmable logic devices (PLDs). Basic computer design with its datapath components and control unit. Introduction to assembly language programming of an off-the-shelf RISC-based microcontroller. Not open to students with credit in CPE/EE 229. 3 lectures, 1 laboratory. Crosslisted as CPE/EE 233.
-
-<|ref|>sub_title<|/ref|><|det|>[[506, 830, 719, 842]]<|/det|>
-## CPE 290. Selected Topics. 1-4 units
-
-<|ref|>text<|/ref|><|det|>[[506, 845, 931, 855]]<|/det|>
-Term Typically Offered: TBD
-
-<|ref|>text<|/ref|><|det|>[[506, 859, 930, 871]]<|/det|>
-Prerequisite: Open to undergraduate students and consent of instructor.
-
-<|ref|>text<|/ref|><|det|>[[506, 883, 934, 908]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[506, 876, 933, 904]]<|/det|>
Directed group study of selected topics. The Schedule of Classes will list title selected. Total credit limited to 8 units. 1 to 4 lectures.
\ No newline at end of file
diff --git a/stage1/sample_00021/document.md b/stage1/sample_00021/document.md
index 672a16ab7aac6b3ab81ddf4a747e9e706a4c1f71..7a6c15ad5951a3853782a5e1eea5c8db8d4cbed7 100644
--- a/stage1/sample_00021/document.md
+++ b/stage1/sample_00021/document.md
@@ -1 +1 @@
-18-013896 5/9/18;1911 5/9/18;1951 5/7/18;1230 5/7/18;1230 5/11/17;0730 12/1/17;2349 12/1/18;1920 5/11/18;1920 5/11/18;2052 5/12/18;0525 5/12/18;0527 5/12/18;1734 5/12/18;1821 5/13/18;0110 5/13/18;0125 5/13/18;0030 5/13/18;0130 5/13/18;1255 5/14/18;0000 5/15/18;0030 5/16/18;2049 5/16/18;2100 5/16/18;2232 5/16/18;2250 5/16/18;2232- 5/16/18;2250 5/16/18;2322 5/16/18;2250 5/16/18;2250
\ No newline at end of file
+Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | |
| | | | | | |
\ No newline at end of file
diff --git a/stage1/sample_00021/document_with_boxes.png b/stage1/sample_00021/document_with_boxes.png
index 5ca4200e41de07e2807f76897c5eb97f67728a8c..f443e0ee548ad5d2993e8d0b885d7f9d069863fb 100644
--- a/stage1/sample_00021/document_with_boxes.png
+++ b/stage1/sample_00021/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:b153bdbe9abf0b99a02ef18ebaaac1e75872e6138325cd378e7119874895f6c0
-size 246391
+oid sha256:a6ca57cb7cb8bb5bfea1bb3837df609ca6b8832336ccf40151b9c6bc019e76ea
+size 270620
diff --git a/stage1/sample_00021/raw_response.md b/stage1/sample_00021/raw_response.md
index 672a16ab7aac6b3ab81ddf4a747e9e706a4c1f71..ee4b10f00220e9cb930349dadfeedb2d9c26bdc6 100644
--- a/stage1/sample_00021/raw_response.md
+++ b/stage1/sample_00021/raw_response.md
@@ -1 +1,3 @@
-18-013896 5/9/18;1911 5/9/18;1951 5/7/18;1230 5/7/18;1230 5/11/17;0730 12/1/17;2349 12/1/18;1920 5/11/18;1920 5/11/18;2052 5/12/18;0525 5/12/18;0527 5/12/18;1734 5/12/18;1821 5/13/18;0110 5/13/18;0125 5/13/18;0030 5/13/18;0130 5/13/18;1255 5/14/18;0000 5/15/18;0030 5/16/18;2049 5/16/18;2100 5/16/18;2232 5/16/18;2250 5/16/18;2232- 5/16/18;2250 5/16/18;2322 5/16/18;2250 5/16/18;2250
\ No newline at end of file
+<|ref|>table<|/ref|><|det|>[[78, 71, 920, 787]]<|/det|>
+
+Nature
Classification | Case
Number | Date/Time
Reported | Date/Time
Occurred | General
Location | Brief Statement | Disposition | Officer |
| Agency Assist | 18-013896 | 5/9/18;1911 | 5/9/18;1911-
5/9/18;1951 | Rockbridge
County | Assisted RBSO with
vehicle pursuit | Inactive | Schriver |
| Property Damage | 18-013642 | 5/7/18;1030 | 5/7/18;1230 | South Institute
Hill lot | Accident with minor
vehicle damage
reported | Inactive | Panebianco |
| Larceny | 18-013788 | 5/8/18;2330 | 12/1/17;0730-
12/12/17;2349 | VMI Barracks | Cadet reported items
missing from trunk
room | Active | Falls |
| Warrant Service | 18-014144 | 5/11/18;1920 | 5/11/18;1920-
5/11/18;1920 | BOQ | Witness subpoena
served on officer | Inactive | Beagan |
| Burglar Alarm | 18-014153 | 5/12/18;0525 | 5/12/18;0525-
5/12/18;0527 | Davidson-
Tucker House | Alarm malfunction | Inactive | Beagan |
| Traffic Accident | 18-014205 | 5/12/18;1734 | 5/12/18;1734-
5/12/18;1821 | Paulette Hall
lot | Minor accident | Inactive | Patterson |
Underage
Possession | 18-014251 | 5/13/18;0110 | 5/13/18;0110-
5/11/18;0125 | VMI Barracks | Underage cadet | Cleared by
arrest | Beagan |
| Vehicle Trespass | 18-014252 | 5/13/18;0030 | 5/13/18;0030-
5/13/18;0130 | VMI Barracks | Unauthorized use of
state vehicle | Inactive | Falls |
| Property Damage | 18-014279 | 5/13/18;1145 | 5/13/18;1255 | VMI Barracks | Padlock assembly
damaged | Inactive | Panebianco |
| Larceny | 18-014485 | 5/15/18;0046 | 5/14/18;2000-
5/15/18;0030 | VMI Barracks | Cadet reported
uniform item missing | Inactive | Schriver |
| Burglar Alarm | 18-014721 | 5/16/18;2049 | 5/16/18;2049-
5/16/18;2100 | JM Hall | Alarm malfunction | Inactive | Patterson |
| Burglar Alarm | 18-014731 | 5/16/18;2232 | 5/16/18;2232-
5/16/18;2250 | JM Hall | Alarm malfunction | Inactive | Patterson |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | |
| | | | | | |
\ No newline at end of file
diff --git a/stage1/sample_00022/document.md b/stage1/sample_00022/document.md
index 1b803d1a30fbac2e991e5f760124e6ab443dd4b7..e50d099da0c9c9b85e3b5965e0981364e9273e81 100644
--- a/stage1/sample_00022/document.md
+++ b/stage1/sample_00022/document.md
@@ -1 +1,23 @@
-1 Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan 2 Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan 3 Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa-ku, Nagoya, Japan 4 Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan 5 Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo-ku, Sapporo, Japan 6 Matsubara Mayflower Hospital, Kato-uchi, Hyogo, Japan 7 Uchida Clinic of Rheumatic Diseases, Sumida-ku, Tokyo, Japan 8 Eisai Co, Ltd., Bunkyo-ku, Tokyo, Japan 9 Abbott GmbH & Co KG, Ludwigshafen, Germany 10 Abbott Laboratories, Abbott Park, Illinois, USA 11 The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi-ku, Kitakyushu, Japan Acknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott. Contributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version. Funding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan). Competing interests TT has received consulting fees, speaking fees, honoraria and/or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra-Zeneca K.K.; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Daiichi-Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol-Myers Squibb; and Otsuka Pharmaceutical Co, and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol-Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co, and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co. NA is an employee of Eisai Co, Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi-Sankyo Co; GlaxoSmithKline K.K.; Astra-Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol-Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K. Patient consent Obtained. Ethics approval An institutional review board approved the study at each site. Provenance and peer review Not commissioned; externally peer reviewed. Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commmercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ References 1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083-90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094-108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75-81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. 5 Smolen JS, Aleatha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor \(\alpha\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMaDalimumab trial. Arthritis Rheum 2003;48:35-45. 9 van de Putte LBA, Atkins C, Malaisie M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644-52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252-62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327-38. 16 Koike T, Hariagi M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498-508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-point counts. Development and validation in a prospective
\ No newline at end of file
+0.3-0.7
+
+of anti- TNF- \(\alpha\) and MTX combination therapy in patients with early RA and high disease activity.
+
+## Author affiliations
+
+Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku- ku, Tokyo, Japan Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku- ku, Tokyo, Japan Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa- ku, Nagoya, Japan Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo- ku, Tokyo, Japan Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo- ku, Sapporo, Japan Matsubara Mayflower Hospital, Kato- shi, Hyogo, Japan Uchida Clinic of Rheumatic Diseases, Sumida- ku, Tokyo, Japan Eisai Co, Ltd., Bunkyo- ku, Tokyo, Japan Abbott GmbH & Co KG, Ludwigshafen, Germany Abbott Laboratories, Abbott Park, Illinois, USA The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi- ku, Kitakyushu, Japan
+
+Acknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott.
+
+Contributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version.
+
+Funding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan).
+
+Competing interests TT has received consulting fees, speaking fees, honoraria and/ or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra- Zeneca K.K.; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Daiichi- Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol- Myers Squibb; and Otsuka Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol- Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co; and received compensation for work on this manuscript from Abbott Japan Co. HA is an employee of Eisai Co; Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi- Sankyo Co; GlaxoSmithKline K.K.; Astra- Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol- Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K.
+
+patients other to distribute, remix, adapt, build upon this work non- commercially,
+
+and license their derivative works on different terms, provided the original work is properly cited and the use is non- commercial. See: http://creativecommons.org/licenses/by- nc/3.0/
+
+## REFERENCES
+
+1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083- 90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094- 108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75- 81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762- 84. 5 Smolen JS, Aletaha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631- 7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26- 37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010;37:2237- 46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti- tumor necrosis factor \(\alpha\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADalimumab trial. Arthritis Rheum 2003;48:35- 45. 9 van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508- 16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti- tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52- week trial. Arthritis Rheum 2004;50:1400- 11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti- tumor necrosis factor- alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563- 71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26- week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64- 71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644- 52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease- affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252- 62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327- 38. 16 Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498- 508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315- 24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in cost see measures, rather than twenty percent? Arthritis Rheum 1998;41:1564- 70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252- 5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective
\ No newline at end of file
diff --git a/stage1/sample_00022/document_with_boxes.png b/stage1/sample_00022/document_with_boxes.png
index 6feaeadbaa40d0f9bcd33e74a24c8648e6131e5f..368a3464523be4628880725548870bf88f304074 100644
--- a/stage1/sample_00022/document_with_boxes.png
+++ b/stage1/sample_00022/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:2bb57301a3d3b80224539cac2dbb97a72fb212d76ca7e5a6c6fec4dbe46aee51
-size 827448
+oid sha256:b2ddb219db8ee7fb8f04dde679d1a474710ba3b66fa05bd23ae90be6e2e11b8f
+size 894773
diff --git a/stage1/sample_00022/raw_response.md b/stage1/sample_00022/raw_response.md
index 1b803d1a30fbac2e991e5f760124e6ab443dd4b7..417f0a4d0f11064c22e4c6f50d0e67c4e226dbc9 100644
--- a/stage1/sample_00022/raw_response.md
+++ b/stage1/sample_00022/raw_response.md
@@ -1 +1,34 @@
-1 Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan 2 Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan 3 Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa-ku, Nagoya, Japan 4 Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan 5 Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo-ku, Sapporo, Japan 6 Matsubara Mayflower Hospital, Kato-uchi, Hyogo, Japan 7 Uchida Clinic of Rheumatic Diseases, Sumida-ku, Tokyo, Japan 8 Eisai Co, Ltd., Bunkyo-ku, Tokyo, Japan 9 Abbott GmbH & Co KG, Ludwigshafen, Germany 10 Abbott Laboratories, Abbott Park, Illinois, USA 11 The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi-ku, Kitakyushu, Japan Acknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott. Contributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version. Funding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan). Competing interests TT has received consulting fees, speaking fees, honoraria and/or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra-Zeneca K.K.; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Daiichi-Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol-Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol-Myers Squibb; and Otsuka Pharmaceutical Co, and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol-Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co, and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co. NA is an employee of Eisai Co, Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi-Sankyo Co; GlaxoSmithKline K.K.; Astra-Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol-Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K. Patient consent Obtained. Ethics approval An institutional review board approved the study at each site. Provenance and peer review Not commissioned; externally peer reviewed. Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commmercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ References 1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083-90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094-108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75-81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. 5 Smolen JS, Aleatha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor \(\alpha\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMaDalimumab trial. Arthritis Rheum 2003;48:35-45. 9 van de Putte LBA, Atkins C, Malaisie M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644-52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252-62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327-38. 16 Koike T, Hariagi M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498-508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-point counts. Development and validation in a prospective
\ No newline at end of file
+0.3-0.7
+
+<|ref|>text<|/ref|><|det|>[[67, 73, 488, 100]]<|/det|>
+of anti- TNF- \(\alpha\) and MTX combination therapy in patients with early RA and high disease activity.
+
+<|ref|>sub_title<|/ref|><|det|>[[68, 114, 169, 125]]<|/det|>
+## Author affiliations
+
+<|ref|>text<|/ref|><|det|>[[67, 124, 488, 315]]<|/det|>
+Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku- ku, Tokyo, Japan Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku- ku, Tokyo, Japan Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, Showa- ku, Nagoya, Japan Department of Medicine and Rheumatology, Graduate School of Tokyo Medical and Dental University, Bunkyo- ku, Tokyo, Japan Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital, Chuo- ku, Sapporo, Japan Matsubara Mayflower Hospital, Kato- shi, Hyogo, Japan Uchida Clinic of Rheumatic Diseases, Sumida- ku, Tokyo, Japan Eisai Co, Ltd., Bunkyo- ku, Tokyo, Japan Abbott GmbH & Co KG, Ludwigshafen, Germany Abbott Laboratories, Abbott Park, Illinois, USA The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Yahatanishi- ku, Kitakyushu, Japan
+
+<|ref|>text<|/ref|><|det|>[[67, 317, 479, 370]]<|/det|>
+Acknowledgements The authors would like to thank all the patients, investigators and support staff who participated in the study, Soura Santra, PhD, formally of Abbott, who provided statistical support, and Mary Beth C. Moncrief, PhD, of MedThink SciCom, for editorial assistance in the writing of this manuscript; this assistance was funded by Abbott.
+
+<|ref|>text<|/ref|><|det|>[[66, 375, 478, 410]]<|/det|>
+Contributors All the authors evaluated the study results, interpreted the data and suggested additional analyses. All authors contributed to the development and critical review of manuscript and approved the final version.
+
+<|ref|>text<|/ref|><|det|>[[66, 413, 486, 438]]<|/det|>
+Funding This study was supported by Abbott Japan Co (Tokyo, Japan) and Eisai Co (Tokyo, Japan).
+
+<|ref|>text<|/ref|><|det|>[[66, 444, 487, 930]]<|/det|>
+Competing interests TT has received consulting fees, speaking fees, honoraria and/ or research grant support from Abbott Japan Co; Astellas Pharma Inc; Astra- Zeneca K.K.; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Daiichi- Sankyo Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Pfizer Japan Inc; and Takeda Pharmaceutical Co. HY has received research grants from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Industrial Pharmaceutical Co; and UCB Japan Co, and speakers honoraria/ consulting fees from Abbott Japan Co; Bristol- Myers Squibb; Chugai Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co; Pfizer Japan Inc; Takeda Pharmaceutical Co; and UCB Japan Co. NI has received research grants from Astellas Pharmaceutical; Chugai Pharmaceutical Co; Eisai Co; and Mitsubishi Tanabe Pharmaceutical Co. NM has received research grants from Abbott Japan Co; Astellas Pharmaceutical; Banyu Pharmaceutical; Chugai Pharmaceutical Co; Daiichi Sankyo Pharmaceutical Co; Eisai Co; Janssen Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co; and Teijin Limited. MM has received research grants from Abbott Japan Co; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Pfizer Japan Inc; Bristol- Myers Squibb; and Otsuka Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. TM has received research grants from Chugai Pharmaceutical Co; Bristol- Myers Squibb; Nippon Kayaku Co; Otsuka Pharmaceutical Co; Takeda Pharmaceutical Co; Eli Lilly Japan K.K.; Eli Lilly and Company; Astellas Pharma Inc; Pfizer Japan Inc; AstraZeneca K.K.; and Santen Pharmaceutical Co; and received compensation for work on this manuscript from Abbott Japan Co. SU has received research grants from Abbott Japan Co; and received compensation for work on this manuscript from Abbott Japan Co. HA is an employee of Eisai Co; Tokyo, Japan. HK is an employee of Abbott GmbH and Co KG, Ludwigshafen, Germany, and may hold Abbott stock or options. VA is an employee of Abbott Laboratories, Abbott Park, Illinois, USA, and may hold Abbott stock or options. YT has received consulting fees, speaking fees and/or honoraria from Mitsubishi Tanabe Pharma Corporation; Abbott Japan Co; Eisai Co; Chugai Pharmaceutical Co; Janssen Pharmaceutical K.K.; Santen Pharmaceutical Co; Pfizer Japan Inc; Astellas Pharma Inc; Daiichi- Sankyo Co; GlaxoSmithKline K.K.; Astra- Zeneca; Otsuka Pharmaceutical Co; Actelion Pharmaceuticals Japan; Eli Lilly Japan K.K.; Nippon Kayaku Co; UCB Japan Co; Quintiles Transnational Japan Co; Ono Pharmaceutical Co; and Novartis Pharma K.K. YT has received research grants from Bristol- Myers Squibb; MSD K.K.; Chugai Pharmaceutical Co; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Abbott Japan Co; Eisai Co; and Janssen Pharmaceutical K.K.
+
+<|ref|>text<|/ref|><|det|>[[65, 934, 472, 954]]<|/det|>
+patients other to distribute, remix, adapt, build upon this work non- commercially,
+
+<|ref|>text<|/ref|><|det|>[[512, 72, 923, 105]]<|/det|>
+and license their derivative works on different terms, provided the original work is properly cited and the use is non- commercial. See: http://creativecommons.org/licenses/by- nc/3.0/
+
+<|ref|>sub_title<|/ref|><|det|>[[514, 139, 599, 151]]<|/det|>
+## REFERENCES
+
+<|ref|>text<|/ref|><|det|>[[512, 152, 926, 944]]<|/det|>
+1 Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1083- 90. 2 Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094- 108. 3 Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75- 81. 4 Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762- 84. 5 Smolen JS, Aletaha D, Bijlsma JW, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631- 7. 6 Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26- 37. 7 van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010;37:2237- 46. 8 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti- tumor necrosis factor \(\alpha\) monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADalimumab trial. Arthritis Rheum 2003;48:35- 45. 9 van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508- 16. 10 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti- tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52- week trial. Arthritis Rheum 2004;50:1400- 11. 11 Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti- tumor necrosis factor- alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563- 71. 12 Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26- week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64- 71. 13 Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644- 52. 14 Miyasaka N, The CHANGE Study Investigators. Clinical investigation in highly disease- affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumato 2008;18:252- 62. 15 Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumato 2012;22:327- 38. 16 Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumato 2012;22:498- 508. 17 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315- 24. 18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35. 19 Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in cost see measures, rather than twenty percent? Arthritis Rheum 1998;41:1564- 70. 20 Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252- 5. 21 Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective
\ No newline at end of file
diff --git a/stage1/sample_00023/document.md b/stage1/sample_00023/document.md
index 91e61f7f0446300f5ce1288b6db7376fdaaff685..7a3d241be1c24e2afb5b213f0a3f52af0302a6c4 100644
--- a/stage1/sample_00023/document.md
+++ b/stage1/sample_00023/document.md
@@ -1 +1,5 @@
-0.5cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm
\ No newline at end of file
+0.5cm 0cm 0cm 0cm 0cm
+
+## Adding Time Limit for Degree Completion for Students who Stop Out-
+
+S. Shannon recommended that the addition of a time limit, and listing it in the catalog, for students who leave a program and then return back after years to finish their degrees under their original curriculum. There should be a set time limit as to how long the student can count courses toward the original degree. It was determined that 10 years would be a appropriate time limit. This would close off the option to graduate from their original program if more than 10 years have passed... Motion was approved
\ No newline at end of file
diff --git a/stage1/sample_00023/document_with_boxes.png b/stage1/sample_00023/document_with_boxes.png
index bbe32ae417250409a828fd083fa09d8e3ac61bf7..48f04efeb6708564b29e9d5436e0b63f24e58918 100644
--- a/stage1/sample_00023/document_with_boxes.png
+++ b/stage1/sample_00023/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:17b4fb35de06027d7fbd454cb91b3e4dd38e09107e9cf08dea8cc0d491822ccb
-size 107229
+oid sha256:1ee409217b0ad6bad6899cf8b31f11b7a0665b455a38d6408ee217c79e6587e8
+size 113872
diff --git a/stage1/sample_00023/raw_response.md b/stage1/sample_00023/raw_response.md
index 91e61f7f0446300f5ce1288b6db7376fdaaff685..14d3148f4c096e319c7f3ce8885170bb2dac2ab6 100644
--- a/stage1/sample_00023/raw_response.md
+++ b/stage1/sample_00023/raw_response.md
@@ -1 +1,7 @@
-0.5cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 3cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 1cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm 0cm
\ No newline at end of file
+0.5cm 0cm 0cm 0cm 0cm
+
+<|ref|>sub_title<|/ref|><|det|>[[115, 206, 710, 227]]<|/det|>
+## Adding Time Limit for Degree Completion for Students who Stop Out-
+
+<|ref|>text<|/ref|><|det|>[[115, 243, 832, 350]]<|/det|>
+S. Shannon recommended that the addition of a time limit, and listing it in the catalog, for students who leave a program and then return back after years to finish their degrees under their original curriculum. There should be a set time limit as to how long the student can count courses toward the original degree. It was determined that 10 years would be a appropriate time limit. This would close off the option to graduate from their original program if more than 10 years have passed... Motion was approved
\ No newline at end of file
diff --git a/stage1/sample_00025/document.md b/stage1/sample_00025/document.md
index f147f88fcff91a125cbc1ef7f86271b896757a63..422b3d2db7d4d31ebc8e4aa439059103f2d0c9ba 100644
--- a/stage1/sample_00025/document.md
+++ b/stage1/sample_00025/document.md
@@ -1,3 +1,3 @@
-5B-10
+5B-10
-| Item | Accounting (based on June 30, 2015 ASC 715 report) | Funding (based on July 1, 2015 valuation report) |
| Service Cost (cost of benefits earned) | N/A - plan frozen | N/A - plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
| Projected Benefit Obligation (PBO) | $15,498,295 | N/A |
| Accumulated Benefit Obligation (ABO)/Funding Target Assets | $15,498,295 | $11,876,067 |
| Balance Sheet Liability | $3,610,049 | $12,025,120 (AVA) |
| AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or curtailment) | $7,690,218 | N/A |
| Cash into Plan | $548,000 (cash basis) | $321,000 (accrual basis) |
| Cash out of Plan | $628,690+$99,236 (expenses) | $628,690+$99,236 (expenses) |
| Liability by Group: | | |
| Actives | $ 4,326,586 | $ 3,046,932 |
| Retired | 6,791,034 | 5,791,017 |
| Terminated Vested | 4,380,675 | 3,038,118 |
| Total | $15,498,295 | $11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
| Demographics: | | |
| Actives | 152 | 152 |
| Retired | 168 | 168 |
| Terminated Vested | 152 | 152 |
| Total | 472 | 472 |
| Discount Rate/Effective Rate | 4.30% (BOY)/4.25% (EOY) | 6.28% |
\ No newline at end of file
+| Item | Accounting (based on June 30,
2015 ASC 715 report) | Funding (based on July 1,2015
valuation report) |
| Service Cost (cost of benefits earned) | N/A-plan frozen | N/A-plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
Projected Benefit Obligation (PBO)
Accumulated Benefit Obligation (ABO)/Funding Target
Assets
Balance Sheet Liability | $15,498,295
$15,498,295
$11,888,246
$3,610,049 | N/A
$11,876,067
$12,025,120 (AVA)
N/A |
AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or
curtailment) | $7,690,218 | N/A |
Cash into Plan
Cash out of Plan | $548,000 (cash basis)
$628,690+$99,236 (expenses) | $321,000 (accrual basis)
$628,690+$99,236 (expenses) |
Liability by Group:
Actives
Retired
Terminated Vested
Total | $ 4,326,586
6,791,034
4,380,675
$15,498,295 | $ 3,046,932
5,791,017
3,038,118
$11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
Demographics:
Actives
Retired
Terminated Vested
Total | 152
168
152
472 | 152
168
152
472 |
| Discount Rate/Effective Rate | 4.30%(BOY)/4.25%(EOY) | 6.28% |
\ No newline at end of file
diff --git a/stage1/sample_00025/document_with_boxes.png b/stage1/sample_00025/document_with_boxes.png
index 422497b3ff3b5300812ef6565ab9ee663184a757..72f1fb4517bf18bd75e6e769b2ae211e8ef082ff 100644
--- a/stage1/sample_00025/document_with_boxes.png
+++ b/stage1/sample_00025/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:c057fb157a146d61e14c605dcbba17f93d2d3a51aabdf0cc391d19c0918a8b9d
-size 249681
+oid sha256:20bfcb9b187b6c78adaa4706206c83542ccd568977fe770e9f5522a042466918
+size 249715
diff --git a/stage1/sample_00025/raw_response.md b/stage1/sample_00025/raw_response.md
index 07c289f8857ac95806902f4e22c6a3e379ae84bf..45ed6ef31b87512747659bc987da0504b6e5e69e 100644
--- a/stage1/sample_00025/raw_response.md
+++ b/stage1/sample_00025/raw_response.md
@@ -1,5 +1,5 @@
-5B-10
+5B-10
-<|ref|>table<|/ref|><|det|>[[185, 271, 814, 844]]<|/det|>
+<|ref|>table<|/ref|><|det|>[[183, 271, 814, 844]]<|/det|>
-| Item | Accounting (based on June 30, 2015 ASC 715 report) | Funding (based on July 1, 2015 valuation report) |
| Service Cost (cost of benefits earned) | N/A - plan frozen | N/A - plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
| Projected Benefit Obligation (PBO) | $15,498,295 | N/A |
| Accumulated Benefit Obligation (ABO)/Funding Target Assets | $15,498,295 | $11,876,067 |
| Balance Sheet Liability | $3,610,049 | $12,025,120 (AVA) |
| AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or curtailment) | $7,690,218 | N/A |
| Cash into Plan | $548,000 (cash basis) | $321,000 (accrual basis) |
| Cash out of Plan | $628,690+$99,236 (expenses) | $628,690+$99,236 (expenses) |
| Liability by Group: | | |
| Actives | $ 4,326,586 | $ 3,046,932 |
| Retired | 6,791,034 | 5,791,017 |
| Terminated Vested | 4,380,675 | 3,038,118 |
| Total | $15,498,295 | $11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
| Demographics: | | |
| Actives | 152 | 152 |
| Retired | 168 | 168 |
| Terminated Vested | 152 | 152 |
| Total | 472 | 472 |
| Discount Rate/Effective Rate | 4.30% (BOY)/4.25% (EOY) | 6.28% |
\ No newline at end of file
+| Item | Accounting (based on June 30,
2015 ASC 715 report) | Funding (based on July 1,2015
valuation report) |
| Service Cost (cost of benefits earned) | N/A-plan frozen | N/A-plan frozen |
| Expense/Minimum Required Contribution | $63,881 | $0 |
Projected Benefit Obligation (PBO)
Accumulated Benefit Obligation (ABO)/Funding Target
Assets
Balance Sheet Liability | $15,498,295
$15,498,295
$11,888,246
$3,610,049 | N/A
$11,876,067
$12,025,120 (AVA)
N/A |
AOCI Balance (offset to retained earnings; represents items not yet reflected in P&L; mainly net losses; amortized over future periods; key items for settlement charges and/or
curtailment) | $7,690,218 | N/A |
Cash into Plan
Cash out of Plan | $548,000 (cash basis)
$628,690+$99,236 (expenses) | $321,000 (accrual basis)
$628,690+$99,236 (expenses) |
Liability by Group:
Actives
Retired
Terminated Vested
Total | $ 4,326,586
6,791,034
4,380,675
$15,498,295 | $ 3,046,932
5,791,017
3,038,118
$11,876,067 |
| PBGC Premiums | $95,928 | $95,928 |
Demographics:
Actives
Retired
Terminated Vested
Total | 152
168
152
472 | 152
168
152
472 |
| Discount Rate/Effective Rate | 4.30%(BOY)/4.25%(EOY) | 6.28% |
\ No newline at end of file
diff --git a/stage1/sample_00026/document.md b/stage1/sample_00026/document.md
index 9540617f0148ab5ddd7e603ebf77a1a93da4056e..4fd789f8666c7dda0b27843d1accdcadcf79342c 100644
--- a/stage1/sample_00026/document.md
+++ b/stage1/sample_00026/document.md
@@ -1,31 +1,11 @@
-0.00
+1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1:
-
+## Friday
-# SECTION VI: SCHEDULE OF EVENTS
+Course preparation. Course walk- through with NCAA site representative. Course review and practice by participants. Packet pick- up. Mandatory coaches meeting.
-# Friday
+## Saturday
-Course preparation.
+Course preparation. Course review and practice by participants. Women's race - race start time to be determined.\* Men's race - race start time to be determined.\* Post- competition recognition ceremony.
-Course walk-through with NCAA site representative.
-
-Course review and practice by participants.
-
-Packet pick-up.
-
-Mandatory coaches meeting.
-
-# Saturday
-
-Course preparation.
-
-Course review and practice by participants.
-
-Women's race - race start time to be determined.*
-
-Men's race - race start time to be determined.*
-
-Post-competition recognition ceremony.
-
-*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.
\ No newline at end of file
+\*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.
\ No newline at end of file
diff --git a/stage1/sample_00026/document_with_boxes.png b/stage1/sample_00026/document_with_boxes.png
index a2c246da01ee3b90271664d7aaf3defa4fb23e86..dff0e697c98a11324a34bcf27db9bc5412eceaf0 100644
--- a/stage1/sample_00026/document_with_boxes.png
+++ b/stage1/sample_00026/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:c30966be29f7c281e334c6c9f9feadb320cb1acfe8482ec9da71dbbe0b1d377f
-size 384564
+oid sha256:89ecff4d716b875ba3957b5d603934202f022e6078c52b1ea2c1a67ad83013c0
+size 366570
diff --git a/stage1/sample_00026/raw_response.md b/stage1/sample_00026/raw_response.md
index 149fb1f0f52e09d17e790d28b5595247e1f92bef..afe9bf59ac2f4736cfc1c046bb6674512b817cb0 100644
--- a/stage1/sample_00026/raw_response.md
+++ b/stage1/sample_00026/raw_response.md
@@ -1,45 +1,16 @@
-0.00
+1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1:
-<|ref|>image<|/ref|><|det|>[[117, 40, 879, 192]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[119, 251, 169, 265]]<|/det|>
+## Friday
-<|ref|>title<|/ref|><|det|>[[571, 213, 882, 231]]<|/det|>
-# SECTION VI: SCHEDULE OF EVENTS
+<|ref|>text<|/ref|><|det|>[[120, 268, 464, 346]]<|/det|>
+Course preparation. Course walk- through with NCAA site representative. Course review and practice by participants. Packet pick- up. Mandatory coaches meeting.
-<|ref|>title<|/ref|><|det|>[[122, 254, 169, 267]]<|/det|>
-# Friday
+<|ref|>sub_title<|/ref|><|det|>[[120, 363, 188, 377]]<|/det|>
+## Saturday
-<|ref|>text<|/ref|><|det|>[[122, 271, 255, 283]]<|/det|>
-Course preparation.
+<|ref|>text<|/ref|><|det|>[[120, 379, 454, 457]]<|/det|>
+Course preparation. Course review and practice by participants. Women's race - race start time to be determined.\* Men's race - race start time to be determined.\* Post- competition recognition ceremony.
-<|ref|>text<|/ref|><|det|>[[122, 286, 462, 298]]<|/det|>
-Course walk-through with NCAA site representative.
-
-<|ref|>text<|/ref|><|det|>[[122, 302, 405, 314]]<|/det|>
-Course review and practice by participants.
-
-<|ref|>text<|/ref|><|det|>[[122, 318, 226, 330]]<|/det|>
-Packet pick-up.
-
-<|ref|>text<|/ref|><|det|>[[122, 335, 315, 346]]<|/det|>
-Mandatory coaches meeting.
-
-<|ref|>title<|/ref|><|det|>[[122, 366, 189, 378]]<|/det|>
-# Saturday
-
-<|ref|>text<|/ref|><|det|>[[122, 383, 255, 394]]<|/det|>
-Course preparation.
-
-<|ref|>text<|/ref|><|det|>[[122, 398, 405, 410]]<|/det|>
-Course review and practice by participants.
-
-<|ref|>text<|/ref|><|det|>[[122, 415, 454, 426]]<|/det|>
-Women's race - race start time to be determined.*
-
-<|ref|>text<|/ref|><|det|>[[122, 430, 433, 442]]<|/det|>
-Men's race - race start time to be determined.*
-
-<|ref|>text<|/ref|><|det|>[[122, 446, 385, 457]]<|/det|>
-Post-competition recognition ceremony.
-
-<|ref|>text<|/ref|><|det|>[[122, 477, 874, 506]]<|/det|>
-*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.
\ No newline at end of file
+<|ref|>text<|/ref|><|det|>[[122, 473, 875, 505]]<|/det|>
+\*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.
\ No newline at end of file
diff --git a/stage1/sample_00027/document_with_boxes.png b/stage1/sample_00027/document_with_boxes.png
index 6edc40ee03fe64ef94b32bce362034f72f3b8ed5..e050035e8961948aa96a4de0393f595bdee21a68 100644
--- a/stage1/sample_00027/document_with_boxes.png
+++ b/stage1/sample_00027/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:f428d647ea84d2fed969a9bf692e232847c66ebfbe1d92eb3598f38ed33b095c
-size 256053
+oid sha256:1636406bdb82f2a00d05e589f5336590c03fabd5e2690230a1e83dba862dcc5b
+size 256740
diff --git a/stage1/sample_00027/figures/sample_00027_fig01.png b/stage1/sample_00027/figures/sample_00027_fig01.png
index 56a1d5b301cbca5ca1d2302e19b81ac12af34c32..d3423ba078df5374ad8ef059cebfb559c9d20a63 100644
--- a/stage1/sample_00027/figures/sample_00027_fig01.png
+++ b/stage1/sample_00027/figures/sample_00027_fig01.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:8a0c22efbd93d536df024681646d0d85a8c4ff066e2bcb90c244e78d3ec21f25
-size 181923
+oid sha256:1d9732d6776712b68425320fdc6977611c0eabe8478f933eef9caf18413627bc
+size 182538
diff --git a/stage1/sample_00027/raw_response.md b/stage1/sample_00027/raw_response.md
index bfd7d6c0a856b303deee155b057092a9f22101b5..0926fa256d553b4314fbeb17826426454092920d 100644
--- a/stage1/sample_00027/raw_response.md
+++ b/stage1/sample_00027/raw_response.md
@@ -1,6 +1,6 @@
5B-6
-<|ref|>image<|/ref|><|det|>[[131, 274, 874, 779]]<|/det|>
+<|ref|>image<|/ref|><|det|>[[127, 273, 877, 782]]<|/det|>
-<|ref|>text<|/ref|><|det|>[[162, 797, 840, 842]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[162, 796, 841, 842]]<|/det|>
* As of July 9, 2015, IRS Notice 2015-49 prohibits sponsors from adopting lump sum windows for participants who currently receive annuity payments.
\ No newline at end of file
diff --git a/stage1/sample_00028/document.md b/stage1/sample_00028/document.md
index 6ebca190d7fbf9f8f6cd1a60bbf4cde9877564fb..e592bc01d7e070cd11528c7c2534d201f61c59ff 100644
--- a/stage1/sample_00028/document.md
+++ b/stage1/sample_00028/document.md
@@ -2,6 +2,4 @@
The prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting "Yes" below.
-
-
Prospective hosts who do not agree with all requirements in this document shall select either "No" or "No with Exception" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.
\ No newline at end of file
diff --git a/stage1/sample_00028/document_with_boxes.png b/stage1/sample_00028/document_with_boxes.png
index 1c645679865f305ccc7fab08b97843f800060b23..ce944344493d5de4f9dc2185107d5f279bcf8021 100644
--- a/stage1/sample_00028/document_with_boxes.png
+++ b/stage1/sample_00028/document_with_boxes.png
@@ -1,3 +1,3 @@
version https://git-lfs.github.com/spec/v1
-oid sha256:aebdc07df65deccb6905a0ec9aa6e9955ac2530b3d5198cae3f95f083e4b3e05
-size 404039
+oid sha256:1615a568849563fab2b8b41cb73fe1ddaf26293aa06ed5e5e89c33740e7567d0
+size 401581
diff --git a/stage1/sample_00028/raw_response.md b/stage1/sample_00028/raw_response.md
index e5488e9670f9775150b5da34bb554e86f2cdde70..a50abc6feefb62ee8e68154f2a7712c5509d5ea7 100644
--- a/stage1/sample_00028/raw_response.md
+++ b/stage1/sample_00028/raw_response.md
@@ -1,9 +1,7 @@
75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales.
-<|ref|>text<|/ref|><|det|>[[128, 618, 882, 702]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[125, 620, 885, 698]]<|/det|>
The prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting "Yes" below.
-<|ref|>image<|/ref|><|det|>[[313, 714, 696, 732]]<|/det|>
-
-<|ref|>text<|/ref|><|det|>[[128, 745, 883, 810]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[129, 747, 884, 810]]<|/det|>
Prospective hosts who do not agree with all requirements in this document shall select either "No" or "No with Exception" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.
\ No newline at end of file
diff --git a/stage1/sample_00030/document.md b/stage1/sample_00030/document.md
index 999fb32296bdc981f4c6b9bfcee7ef0151901101..49752222f2288043f38db5b2f99db5c58d27d99b 100644
--- a/stage1/sample_00030/document.md
+++ b/stage1/sample_00030/document.md
@@ -1,11 +1,14 @@
-145 (Fig. 6B), which over-express EGFR (Fig. 6C).
+145 (Fig. 6B), which over-express EGFR (Fig. 6C).
+
-| ENGL 3335 | Rhetorical Analysis* |
| FREN 3305 | Introduction to French Literature I* |
| FREN 3306 | Introduction to French Literature II* |
| FREN 4304 | Topics in French Literature of the Eighteenth Century* |
| FREN 4305 | Topics in French Literature of the Nineteenth Century* |
| MUSC 3341 | Music History 1: Ancient Greece to Mozart* |
| MUSC 3342 | Music History 2: Classical Era to the Present* |
| PHIL | All upper division courses** |
| PLSI 3352 | Civil Rights and Liberties |
| PLSI 3361 | Classical Political Thought |
| PSYC 2401 | Statistics and Research Methods |
| PSYC 3451 | Clinical Psychology* |
| RELI 1320 | Ethical Issues in Religious Perspective |
| RELI | All upper division courses* |
| SPAN 3321 | Spanish Cinema* |
+
+Principles of Organizations and Communities
+
+| ENGL 3335 | Rhetorical Analysis* |
| FREN 3305 | Introduction to French Literature I* |
| FREN 3306 | Introduction to French Literature II* |
| FREN 4304 | Topics in French Literature of the Eighteenth Century* |
| FREN 4305 | Topics in French Literature of the Nineteenth Century* |
| MUSC 3341 | Music History 1: Ancient Greece to Mozart* |
| MUSC 3342 | Music History 2: Classical Era to the Present* |
| PHIL | All upper division courses** |
| PLSI 3352 | Civil Rights and Liberties |
| PLSI 3361 | Classical Political Thought |
| PSYC 2401 | Statistics and Research Methods |
| PSYC 3451 | Clinical Psychology* |
| RELI 1320 | Ethical Issues in Religious Perspective |
| RELI | All upper division courses* |
| SPAN 3321 | Spanish Cinema* |
+
+<|ref|>table_caption<|/ref|><|det|>[[132, 499, 468, 515]]<|/det|>
+Principles of Organizations and Communities
+
+<|ref|>table<|/ref|><|det|>[[114, 533, 848, 770]]<|/det|>
+